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Metabolic syndrome (MetS) is a cluster of metabolic disorders, including increased fasting
glucose, blood pressure, plasma triglyceride, reduced high-density lipoprotein cholesterol
and abdominal obesity. It leads to an increased risk of cardiovascular disease and diabetes. The growing prevalence of MetS is strongly related to the increasing prevalence of
overweight/obesity. As an antioxidant, lycopene can reduce the risk of MetS. However, it
is unclear whether lycopene has similar effects among overweight/obese individuals and
whether lycopene can reduce the risk of mortality among individuals with MetS. The purpose of this study was to explore the roles of lycopene in the prevalence and mortality of
MetS. Specifically, the main objective was to examine the associations between serum
lycopene or the ratio of serum lycopene to serum triglyceride and MetS, and the association between the ratio and mortality among individuals with MetS. In addition, the possible
additive effects of physical activity and lycopene on MetS and mortality were studied. To
achieve these objectives, analyses were conducted with participants aged 20 years and
older from the NHANES 2001-2006. The tertile rank method was used to divide participants into three groups according to serum lycopene or the ratio. Logistic regression and
Cox models were used for association analyses. With serum lycopene, the associations
between lycopene and MetS were only significant for normal weight/overweight (p<0.05),
but not for obese participants (p>0.05). While with the ratio, the associations between
lycopene and MetS were significant not only for normal weight/overweight (p<0.05), but
also for obese participants (p<0.05). Compared with the first tertile group, both the third

and second tertile groups had significantly reduced hazard ratios of mortality for participants with MetS. The additive effect of lycopene and physical activity was significant for
overweight (p<0.05) but not for obese participants (p>0.05). There was no an additive
effect of lycopene and physical activity on mortality among participants with MetS. Therefore, the study adds new evidence that the ratio of serum lycopene to serum triglyceride
has significant associations with morbidity and mortality of MetS.
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CHAPTER 1 INTRODUCTION
1.1. Metabolic Syndrome
Metabolic syndrome is a cluster of metabolic disorders, including increased fasting
glucose, blood pressures, plasma triglyceride, and reduced high-density lipoprotein (HDL)
cholesterol concentrations and abdominal obesity [1]. According to the National Cholesterol Education Program’s Adult Treatment Panel III, to be diagnosed with metabolic
syndrome, an individual has to meet three or more of the following criteria: abdominal
obesity (waist circumference>40 inches for men and>35 inches for women); hypertriglyceridemia (serum triglyceride≥1.69 mmol/L); low HDL-cholesterol (HDL<1.04 mmol/L for
men and<1.29 for women); hypertension (≥130/85 mmHg) and high fasting glucose (fasting glucose≥6.1 mmol/L) [2]. With the diagnosis criteria, approximately 27% of adults,
aged 20 years and older, had metabolic syndrome in 2000 based on the National Health
and Nutrition Examination Survey (NHANES) 1999–2000 [2]. Metabolic syndrome is common among overweight and obese individuals, and leads to an increased risk of
cardiovascular disease and type 2 diabetes mellitus [1, 2]. Additionally, metabolic syndrome is associated with increased risks for certain cancers, including breast [3],
endometrial [4], colorectal [5] and biliary tract cancers [6], and an increased risk for allcause mortality [7, 8]. Thus, given the number of affected individuals and the associated
disease risks, metabolic syndrome is an important public health concern in the United
States.
Although the mechanisms behind metabolic syndrome are not entirely clear, accumulating evidence supports that chronic inflammation and oxidative stress play important
roles in its development [9, 10]. For example, increased body mass index (BMI) is found
to increase inflammation and oxidative stress production [11-13]. Also, the prevalence of
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metabolic syndrome strongly correlates with an increased prevalence of overweight and
obesity [11-13].
1.2. Health Effects of Lycopene
There have been a number of different strategies or interventions intended to mitigate
the oxidative stress and/or inflammation. One is the therapeutic drug strategy. For example, salsalate, a traditional anti-inflammatory medication, can prevent the metabolic
syndrome in obese non-diabetic individuals [14]. Probucol, a potent anti-oxidant drug, has
been in clinical use during the past few decades for prevention of cardiovascular diseases
[15]. While these therapeutic drug strategies that target weight-related oxidative stress
and/or inflammation can potentially reduce chronic disease burdens, often these anti-oxidants and anti-inflammatory drugs have serious side effects in long-term disease
prevention. For example, approximately 30% of patients discontinued use of salsalate because of gastrointestinal symptoms and tinnitus [16] and many patients discontinued use
of probucol because of the space between the start of the Q wave and the end of the T
wave (Q-T interval) prolongation [17].
A diet rich in antioxidants is another potential approach to reduce oxidation and inflammation. Therefore, nutrient intake from food, such as lycopene, may be an ideal option for
long-term disease prevention. As a nutrient, lycopene is mainly contained in tomatoes and
other vegetables or fruits, such as red carrots and watermelons. The biological mechanisms of lycopene on metabolic syndrome and chronic diseases include alleviating
oxidative stress and inhibiting inflammation in the body [18-22]. Studies found there is a
significant association between metabolic syndrome and lycopene [23-25]. For example,
Sluijs et al, found that higher lycopene intake is associated with a lower prevalence of
metabolic syndrome in middle-aged and elderly men [23]. Liu et al. found that higher serum lycopene levels were associated with a lower prevalence of metabolic syndrome in

3
middle-aged and elderly Chinese adults [24]. Yeo et al. also found there is a significantly
positive association between metabolic syndrome and serum lycopene among Korean
men [25]. Further, epidemiologic studies have shown that lycopene can significantly reduce the risks of chronic diseases. For example, since the first report that lycopene can
reduce the incidence rate of prostate cancer in 1995 [26], lycopene has been found to be
inversely associated with breast, cervical, ovarian, liver and other organ sites cancers [27].
In addition to tumor-suppressing activity, lycopene is found to decrease the risks of developing other chronic diseases, such as cardiovascular disease [28-30] and cerebrovascular
disease [31].
Despite accumulating evidence to support health effects of lycopene, it is not clear
whether lycopene has similar effects among individuals who are overweight or obese.
Many recent studies on lycopene have focused on people who are overweight or obese
[32-37]; however, the results remain inconclusive. For example, some studies found that
lycopene intervention can significantly reduce inflammation and oxidative stress in participants who are overweight and obese [32-35], while other studies did not find significant
associations between lycopene and inflammation and oxidative stress in overweight or
obese individuals [36, 37].
One of the potential reasons for varying effects of lycopene is differences in the
amount of serum lycopene in these studies. Two cell culture studies found a dose-dependent relationship between the serum lycopene concentration and the amount of
reduction in inflammation and oxidative stress [38, 39]. These findings explain non-significant results of lycopene studies when the serum concentration was notably lower.
Another point to consider when interpreting the research findings on lycopene is variations
in the level of oxidation and inflammation in different individuals. By definition, compared
to normal weight individuals, overweight and obese individuals should have higher levels
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of oxidation and inflammation. It is possible that among overweight and obese individuals
with already high oxidation and inflammation levels, a substantially larger amount of lycopene needs to be applied in order to have observable changes. This may indicate that the
lycopene effect on oxidation and inflammation is not linear; there may be some thresholds
in the BMI levels (as indicators of existing inflammation and oxidation levels) at which
points, considerably more lycopene needs to be added as nutrients before its positive
effects can be observed.
A triglyceride is an ester consisting of one glycerol molecule bonded with three fatty
acid molecules. As a serum lipid, it helps enable the bidirectional transference of adipose
fat and blood glucose from the liver. There is a strong association between serum triglyceride and BMI statuses [40]. Furthermore, serum concentration of triglyceride is
significantly associated with increased oxidative stress [41] and increased levels of inflammation [42]. Therefore, serum triglyceride can be regarded as an indicator of existing
inflammation and oxidation levels in the body.
Taken together, health effects of serum lycopene may depend not only on serum concentrations, but also on the amount of inflammation and/or oxidative stress in the body.
Therefore, the ratio of the serum concentration of lycopene to the amount of inflammation
and/or oxidative stress can better predict the association between lycopene and positive
health effects than with only the serum concentration of lycopene. There is no method to
directly measure the amount of inflammation and/or oxidative stress in the body. Given
that serum triglyceride is an indicator of existing inflammation and oxidation levels in the
body, this study used serum triglyceride to represent the amount of inflammation and/or
oxidative stress.
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1.3. Roles of Physical Activity
Physical activity has been shown to prevent metabolic syndrome for individuals who
are overweight and obese [43-45]. The biological mechanisms by which physical activity
prevents metabolic syndrome include reducing abdominal adipose tissue, serum concentration of triglyceride, and blood pressure, and increasing high-density lipoprotein and
insulin sensitivity [46]. In addition, physical activity can prevent metabolic syndrome by
decreasing inflammation and inducing an anti-inflammatory environment [47, 48]. For example, physical activity can simultaneously decrease inflammatory cytokines, such as
TNF-α and interleukin-6, and increase anti-inflammatory cytokines, such as interleukin-10
[49-51].
There is a similarity in the way lycopene and physical activity both impact metabolic
syndrome. For example, both decrease inflammatory cytokines like TNF-α and interleukin6 [20, 21 and 52] and increase anti-inflammatory cytokines like interleukin-10 [53, 54]. Due
to common biological mechanisms by which physical activity and serum lycopene reduce
the risk of metabolic syndrome by regulating inflammatory cytokines, it is natural to posit
that there will be an additive effect between physical activity and serum lycopene on metabolic syndrome. Although both physical activity and lycopene can reduce the risk of
morbidity and mortality of metabolic syndrome, studies suggest that the effects of physical
activity or lycopene alone are insufficient to substantially reduce the risk of metabolic syndrome for overweight and obese individuals [44]. Examining the additive effect between
physical activity and serum lycopene is important for further reducing the risk of metabolic
syndrome among individuals who are overweight and obese.
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1.4. Potential Effects of Lycopene on Mortality
As mentioned above, metabolic syndrome has an increased risk of all-cause mortality
as well as cardiovascular related mortality [7, 8]. Although the reasons for the higher mortality are not entirely clear, accumulating epidemiologic evidence supports that higher
mortality may be largely attributable to increased risks of cardiovascular disease, diabetes
and stroke-related morbidity and mortality in individuals with metabolic syndrome [8, 55
and 56]. There are more inflammation and oxidative stress in individuals with metabolic
syndrome than individuals without metabolic syndrome [57]. Increased inflammation and
oxidative stress lead to the increased risk of cardiovascular disease, diabetes and stroke
[58-60].
Past epidemiologic studies suggest that lycopene can reduce the risk of cardiovascular diseases [28-30] and stroke [31]. In addition, lycopene was found to reduce the
mortality in the general population [61, 62], in patients with Alzheimer’s disease, and in
patients with obstructive lung function [63, 64]. However, some intervention studies did
not find significant associations between lycopene and cardiovascular diseases [65, 66]
and mortality [67]. Therefore, results on the beneficial role of lycopene as an antioxidant
in the prevention of cardiovascular diseases and mortality remain conflicted [68]. Although
all studies claimed that serum concentration of lycopene increased, high increase of serum lycopene at the baseline (0.371umol/L for women and 0.258 umol/L for men) had a
significant positive effect on mortality [61] while a small increase of serum lycopene at the
baseline (0.16 μmol/L) had no significant positive effect on mortality [67]. Therefore, different criteria for change in serum concentration of lycopene may be an alternative
explanation for these inconsistent results. For this reason, the ratio of the serum concentration of lycopene to the amount of inflammation and/or oxidative stress (relative serum
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concentration of lycopene) was used to predict the association between lycopene and
mortality.
1.5. Effects of Physical Activity on Mortality
A study found that physical activity is significantly associated with reduced mortality in
patients with metabolic syndrome [69]. In this prospective study of more than 13,000 men
and women with metabolic syndrome, after 10 years following-up, the authors found that
individuals with metabolic syndrome who reported high levels of physical activity at baseline were at a reduced risk of death from all causes compared to those who reported no
physical activity [69]. However, metabolic syndrome has a high risk of all-cause mortality
as well as cardiovascular related mortality [7, 8]. Therefore, to maximize the reduction of
deaths among individuals with metabolic syndrome, it is necessary to explore whether a
combination of physical activity and lycopene has a stronger effect on mortality than physical activity or lycopene alone.
1.6. Summary of Research Gaps
Gap 1: Lycopene can reduce the risk of metabolic syndrome by alleviating oxidative
stress and inhibiting inflammation; the health effects of lycopene on inflammation and oxidative stress are not significant for obese individuals; the question is whether the health
effect of lycopene on metabolic syndrome is significant among obese individuals.
Gap 2: Due to the fact that the effects of lycopene depends on the serum concentration
of lycopene and the amount of inflammation and oxidative stress, the question is whether
the ratio of serum lycopene to the amount of inflammation and oxidative stress can better
predict the health effects of lycopene.
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Gap 3: Metabolic syndrome has an increased risk of mortality, lycopene can reduce
the risk of mortality in general population and some patients, and the question is whether
lycopene can reduce the risk of mortality among individuals with metabolic syndrome.
Gap 4: Although both physical activity and lycopene can reduce the risk of metabolic
syndrome, both alone are insufficient for the risk. The question is whether physical activity
and lycopene have an additive health effect on metabolic syndrome.
Gap 5: Although both physical activity and lycopene can reduce the risk of mortality of
metabolic syndrome, both alone are insufficient for the risk. The question is whether physical activity and lycopene have an additive health effect on mortality.
1.7. Study Purpose and Specific Aims
The purpose of this study was to explore the roles of lycopene on the morbidity and
mortality of metabolic syndrome by using a large population-based database. There were
five specific aims.
Specific Aim 1: To examine the association between serum concentration of lycopene
and the prevalence of metabolic syndrome for individuals with different BMI levels. Hypothesis: The association between serum lycopene and metabolic syndrome is influenced
by different BMI levels.
Specific Aim 2: To examine the association between the ratio of serum lycopene to
serum triglyceride and the prevalence of metabolic syndrome for individuals with different
BMI levels. The association between the ratio of serum lycopene to serum triglyceride and
metabolic syndrome is influenced by different BMI levels.
Specific Aim 3: To examine the effect of lycopene on mortality in individuals with metabolic syndrome. Hypothesis: Serum lycopene can reduce the risk of mortality for
individuals with metabolic syndrome.
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Specific Aim 4: To examine the possible additive effect of physical activity and serum
lycopene on the prevalence of metabolic syndrome among overweight and obese individuals.
Specific Aim 5: To examine the possible additive effect of physical activity and serum
lycopene on mortality among individuals with metabolic syndrome.
1.8. Theoretical Framework
An increased risk of metabolic syndrome occurs in overweight/obese individuals due
to increased chronic inflammation and oxidative stress [11-13]. Lycopene, as a natural
antioxidant, can alleviate oxidative stress and inhibit inflammation [18-22]. Therefore, increased serum lycopene has the potential to decrease the risk of metabolic syndrome in
individuals who are overweight and obese.
However, the health effects of lycopene on reducing inflammation and oxidative stress
in individuals who are overweight and obese remain inconclusive [32-37]. Health effects
of serum lycopene may depend not only on serum concentrations, but also on the amount
of inflammation and/or oxidative stress in the body. Therefore, the ratio of the serum concentration of lycopene to the amount of inflammation and/or oxidative stress can better
predict the association between lycopene and positive health effects than serum concentration of lycopene alone can. There is no method to directly measure the amount of
inflammation and/or oxidative stress in the body. Given the strong associations between
oxidative stress and inflammation, this study used serum triglyceride to represent the
amount of inflammation and/or oxidative stress. Therefore, in this study, we examined the
health effect of lycopene on metabolic syndrome based on the ratio of serum lycopene to
serum triglyceride.
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Metabolic syndrome also increases the risk of death from all causes as well as cardiovascular diseases [7, 8]. In addition to decreasing the risk of cardiovascular diseases,
lycopene was also found to reduce the mortality in the general population [61, 62] and in
patients with Alzheimer’s disease or obstructive lung function [63, 64]. Therefore, serum
lycopene also has a potential to reduce the risk of mortality for individuals with metabolic
syndrome. However, some intervention studies did not find significant associations between lycopene and cardiovascular diseases [65, 66] and mortality [67]. Different criteria
for the amount of increase in the serum concentration of lycopene may be an alternative
explanation for these inconsistent results. For this reason, the ratio of the serum concentration of lycopene to the amount of inflammation and/or oxidative stress (relative serum
concentration of lycopene) was used to predict the association between lycopene and
mortality in this study.
As a healthy lifestyle, physical activity can reduce the risk of metabolic syndrome [4345] and mortality [69]. Due to common biological mechanisms by which physical activity
and serum lycopene regulate inflammatory cytokines [20, 21, 49-54], it is natural to posit
that there will be additive effects between physical activity and serum lycopene on metabolic syndrome and mortality. Therefore, we examined the possible additive effects of
physical activity and lycopene on metabolic syndrome and mortality in this study.
Figure 1 shows a conceptual model developed for this study. Overweight and obese
individuals have a higher risk to develop metabolic syndrome than normal weight individuals. Individuals with metabolic syndrome have a higher risk of mortality than individuals
without metabolic syndrome. An increased risk of metabolic syndrome occurs in overweight/obese individuals due to increased chronic inflammation and oxidative stress.
Lycopene, as a natural antioxidant, can alleviate oxidative stress and inhibit inflammation.
Therefore, we hypothesized that lycopene has the potential to reduce the risk of metabolic
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syndrome among overweight and obese individuals. Metabolic syndrome also increases
the risk of death from all causes as well as cardiovascular diseases. In addition to decreasing the risk of cardiovascular diseases, lycopene was also found to reduce the
mortality in the general population and patients with Alzheimer’s disease or obstructive
lung function. Therefore, we also hypothesized that lycopene has the potential to reduce
the risk of mortality for individuals with metabolic syndrome. In addition, due to common
biological mechanisms by which physical activity and serum lycopene regulate inflammatory cytokines, we hypothesized that there were additive effects of physical activity and
lycopene on metabolic syndrome and mortality.
Figure 1. Conceptual model of metabolic syndrome

1.9. Scope of the Study
The study took advantage of the NHANES database, a unique population-based survey and laboratory measruments, which collects information about the health and nutrition
intake of adults and children [70]. The NHANES sample represents the United States noninstitutionalized civilian population residing in the 50 states and the District of Columbia.
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The data collection in NHANES included a home interview and a follow-up physical examination. The CDC institutional review board approved the survey; in addition, before
participants took part in the study, they all signed written informed consent forms. In this
study, only adult participants who were at least 20 years of age were included. The combination of NHANES 2001–2006 included 15,431 adult participants (7,341 men and 8,090
women).
1.10. Summary
In this chapter, we first described the background of the research problems. Metabolic
syndrome is an important health condition because it is directly related to a high risk of
chronic diseases and mortality. The growing prevalence of metabolic syndrome is related
to the increasing prevalence of overweight and obesity. Therefore, exploring healthy lifestyles, such as diet and physical activity, is very important to reduce the prevalence and
mortality of metabolic syndrome for overweight and obese individuals. We stated our research purposes, specific aims/research hypotheses and theoretical framework. Lastly,
we described the population source for this study. The data in this study was obtained
from the NHANES from 2001 to 2006. The study is important because the findings can
provide an important analysis method (the ratio of serum lycopene to serum triglyceride)
for future studies between lycopene and health effects.
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CHAPTER 2 REVIEW OF THE LITERATURE
2.1. Overweight and Obesity
Overweight and obesity are referred to be a body weight that’s greater than what is
considered healthy for a certain height [71]. BMI, an expression with weight divided by
height squared (kg/m2), is a common measure for classification of overweight and obesity
because it is inexpensive and easy to use for clinicians and for the general public. An adult
with a BMI between 25.0 and 29.9 kg /m2 is considered to be overweight and an adult with
a BMI of 30 kg/m2 or higher is considered to be obese. For children and adolescents, when
a BMI number is plotted on a specific growth chart, we can find a relative position for this
BMI (specific gender-age-percentile). If his/her BMI is located between 85th and 95th percentile, he/she is considered as overweight; if his/her BMI is located equal or greater than
95th percentile, he/she is considered as obese [72].
According to the Global Burden of Disease Study, approximately 35% adults aged 20
years and above were overweight or obese in 2008 around the world [73]. Obesity epidemic has become a major public health problem in the United States. The prevalence of
obese adults had more than doubled from 15% in 1976-1980 to 36% in 2009-2010 in the
country [74]. The prevalence of adults who are overweight or obese was 68% for the period 2011-2012 [75]. This means two-thirds of American adults are either overweight or
obese. According to Allison et al., 280,000 to 325,000 deaths per year are attributable to
overweight and obesity and their complications in the United States. [76].
Overweight and obesity place a dramatic burden on families and society. There are
many methods for economic estimation; the common methods include the direct and indirect cost estimations [77]. Direct costs include physician visit and hospital or nursing home
care. Indirect costs include the income loss resulted from work loss, and premature death.
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In 1995, the total estimated costs related to overweight and obesity were approximately
$99.2 billion, including $51.6 billion in direct costs and $47.6 billion in indirect costs [77].
By 2000, the total costs of overweight and obesity were $117 billion, with $61 billion in
direct costs and $56 billion in indirect costs [78]. For youths aged 6 to 17 years, overweight
and obesity-related hospital costs had increased three times from $35 million (1979-1981)
to $127 million (1997-1999) per year [79]. Overweight and obesity had led to over 1.3
billion long-term care patient days and over $68 billion Medicaid costs (in 2012 value)
among baby boomers [80].
2.2. Roles of Excess Weight and Metabolic Syndrome in Development of Chronic
Diseases
These significant public health burdens related to overweight and obesity mainly contribute to its high risk of developing chronic diseases, such as cardiovascular disease [81,
82], cerebrovascular disease [83] diabetes [84], osteoarthritis [85], non-alcoholic fatty liver
disease [86] and cancers [87]. Cardiovascular disease, cerebrovascular disease and diabetes are some of the leading causes of mortality in the world [88]. Accumulating
epidemiological evidence supports that a cluster of metabolic disorders in overweight and
obese individuals is related to high risks of developing cardiovascular and cerebrovascular
diseases. The cluster of metabolic disorders includes insulin resistance or higher fasting
glucose, higher blood pressures, higher plasma triglyceride, and lower HDL cholesterol
concentrations. For example, the growing prevalence of insulin resistance is significantly
related to increasing BMI [89]. The prevalence of hypertension is higher in obese (35.7%)
and overweight (26.4%) than in normal weight adults (19.8%). And the prevalence of
dyslipidemia is higher in obese (49.7%) and overweight (44.2%) than in normal weight
adults (28.6%) [90]. This cluster of metabolic disorders was named as insulin-resistance
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syndrome (syndrome X) at first [91, 92], then was named as metabolic syndrome lately
[93].
2.3. Metabolic Syndrome
According to the American Heart Association and the National Heart, Lung, and Blood
Institute, metabolic syndrome is defined as a condition in which a group of metabolic risk
factors exist in an individual. These risk factors, such as obesity, dyslipidemia, elevated
blood pressure, insulin resistance, are directly related to a high risk of cardiovascular disease and type 2 diabetes mellitus [1].
Currently, there are at least three clinical diagnosis criteria recommended for metabolic syndrome. According to the World Health Organization (WHO), if an individual has
glucose intolerance, impaired glucose tolerance (IGT) or diabetes mellitus (DM) and /or
insulin resistance together with two or more of the following components: raised arterial
pressure (greater and equal to 140/90 mmHg); dyslipidemia [elevated plasma triglycerides
(greater and equal to 1.7mmol/L) and/or decreased HDL-cholesterol (less than 0.9 mmol/L
for men and less than 1.0 mmol/L for women)]; central obesity (waist to hip ratio great than
0.90 for men and great than 0.85 for women) and/or BMI greater than 30 kg/m2; and microalbuminuria (urinary albumin excretion rate greater and equal to 20 ug/min or albumin
to creatinine ratio greater and equal to 30 mg/g) [94]. The American Association of Clinical
Endocrinologists proposes another set of clinical criteria: overweight/obesity (BMI greater
and equal to 25 kg/m2); elevated triglycerides (greater and equal to 1.69 mmol/L); low
HDL-cholesterol (less than 1.04 mmol/L for men and less than 1.29 mmol/L for women);
elevated blood pressure (greater and equal 130/85 mmHg); two hours post-glucose challenge (greater than 140 mg/dl); fasting glucose (between 110 mg/dl and 126 mg/dl) and
other risk factors (such as family history of T2DM, hypertension, or CVD; sedentary lifestyle; advancing age and high risk ethnic groups) [95]. According to the National
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Cholesterol Education Program’s Adult Treatment Panel III report (ATP III), if an individual
has three or more of the following criteria, he/she will be diagnosed with metabolic syndrome: abdominal obesity (waist circumference greater than 102 cm for men and greater
than 88 cm for women); hypertriglyceridemia (greater and equal to 1.69 mmol/L); low HDLcholesterol (less than 1.04 mmol/L for men and less than 1.29 mmol/L for women); hypertension (greater and equal to 130/85 mmHg) and high fasting glucose (greater and equal
to 6.1 mmol/L) [96].
Using the ATP III criteria, Ford et al. found the prevalence of metabolic syndrome
among the United States adults was 24.0%. The study was based on the third National
Health and Nutrition Examination Survey (NHANES III) from 1988 to 1994 [97].
Due to increased prevalence of overweight and obesity in the United States, the prevalence of metabolic syndrome continues to increase. Using the ATP III criteria, Aguilar et
al. found the prevalence of metabolic syndrome among United States adults to be 32.9%
during 2003-2004 and 34.7% during 2011-2012 based on NHANES 2003-2012 [98].
2.4. Inflammation, Oxidative Stress, Obesity and Metabolic Syndrome
Why is the percent of metabolic syndrome higher in individuals who are overweight
and obese than individuals who have normal weight? Inflammation and oxidative stress
are the central mechanisms connecting overweight and obesity to metabolic syndrome
[11, 12, 99, 100]. Studies show that adipose tissue is one of the sources of inflammation
and oxidative stress [101-105]. For example, many inflammatory cytokines, such as TNFα, IL-1β, IL-6, IL-8, IL-10 and leptin can produce in adipose tissue [101-103]. In addition
to cytokines, adipose tissue can produce lipid peroxides and oxidative stress, such as
reactive oxidative metabolites [104, 105]. Therefore, excess adipose tissue can lead to
more inflammation and oxidative stress in individuals who are overweight and obese. For
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example, there are significantly increased oxidative stress (oxidized low-density lipoprotein and reactive oxygen species) and low-grade inflammation (C-reactive protein and
leptin) in obese individuals when compared to normal weight individuals [13, 106]. In addition, antioxidant enzymes and total plasma antioxidant capacity are suppressed in
overweight and obese condition. For example, dietary-induced obesity can decrease antioxidant enzymes, such as superoxide dismutase (SOD), glutathione peroxidase in adult
rats [107]. Furthermore, adipose glutathione peroxidase was greatly suppressed by prooxidative conditions such as high levels of TNF-α and hypoxia [108].
2.5. Prevention and Treatment of Metabolic Syndrome
Prevention of metabolic syndrome is needed to address several risk factors and reduce inflammation and oxidative stress in the body while treatments of metabolic
syndrome are needed to control the components of metabolic syndrome.
Although metabolic syndrome can be caused by genetic factors, aging, smoking, unhealthy diets and inactive lifestyles [98, 109 and 110], overweight and obesity is the primary reason for metabolic syndrome [111]. Therefore, in addition to quitting smoking and
keeping an active lifestyle, controlling weight is very important for the prevention of metabolic syndrome. Preventing overweight and obesity is an important step to reduce the
prevalence of metabolic syndrome and chronic disease conditions and reduce the financial burden on patients’ families and society. However, although some interventions
related to overweight and obesity have been developed to improve the health of individuals and populations in recent years [112-114], the prevalence of overweight and obesity
in the United States is still a huge problem [75].
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Overweight and obesity are associated with increased oxidative stress and chronic
inflammation status that favors the development of metabolic syndrome. Therefore, alleviating oxidative stress and/or suppressing inflammation is an alternative strategy to
reduce the prevalence of metabolic syndrome among individuals who are overweight and
obese. One is the therapeutic drug strategy. For example, salsalate, a traditional antiinflammatory medication, can prevent metabolic syndrome in obese non-diabetic individuals [14]. Probucol, a potent anti-oxidant drug, has been in clinical use during the past few
decades for the prevention of cardiovascular diseases [15]. However, these therapeutic
drug strategies that target weight-related oxidative stress and/or inflammation can potentially reduce chronic disease burden, but often anti-oxidants and anti-inflammatory drugs
have serious side effects in long-term disease prevention, such as approximately 30% of
patients discontinued the use of salsalate because of gastrointestinal symptoms and tinnitus [16] and many patients discontinued the use of probucol because of QT interval
prolongation [17].
A diet rich in antioxidants is another potential approach to reduce oxidation and inflammation. Carotenoids are a group of antioxidants that are found in fruits and vegetables.
There are over 600 different carotenoids identified, however, approximately 90% of carotenoids are represented by the common dietary carotenoids including α-carotene, βcarotene, lycopene, lutein and β-cryptoxanthin [115]. Α-carotene, β-carotene, and β-cryptoxanthin can convert to retinal and have vitamin A activity while lycopene and lutein
cannot convert to retinal and therefore have no vitamin A activity [116]. After absorption,
carotenoids are mainly distributed in the adipose tissue [117, 118]. Β-carotene and lycopene are the predominant components of carotenoids in the adipose tissue, approximately
20% of total carotenoids respectively [118]. Due to its higher tissue concentration and
vitamin A activity, β-carotene is regarded as the main research interest in epidemiological
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studies [119-122]. However, β-carotene may play double roles since β-carotene can promote health when taken at a lower level while β-carotene can bring adverse effects when
taken at a higher level [115,120 and 121]. In addition, lycopene is discovered to be the
most potent antioxidant; therefore, lycopene has attracted the attention of scientists
around the world [123, 124].
2.6. Lycopene
As a natural antioxidant, lycopene can alleviate oxidative stress induced in animal
models [125, 126]. Dietary intake of tomatoes or purified lycopene supplementation has
also decreased the oxidative damages in humans [18, 19, 127 and 128]. For example,
lycopene supplementation can reduce 86% of induced lipid peroxidation in monkey cells
[125]. In humans, consumption of tomato products can reduce lipoprotein sensitivity to
oxidative damage [18] and reduce biomarkers of oxidative stress, such as lipid peroxidation and DNA damage [19, 127 and 128].
Lycopene is a red pigment found primarily in tomatoes. Structurally, lycopene, assembled from eight isoprene units, is a tetraterpene that is not soluble in water. Like all other
carotenoids, lycopene is a polyunsaturated hydrocarbon. Lycopene's antioxidant activity
attributes to its eleven conjugated double bonds [129]. The main source of lycopene for
humans is from dishes prepared with vegetables and fruits which contain lycopene. Lycopene is mainly contained in tomatoes and other vegetables or fruits, such as red carrots
and watermelons. There is about 3,014 µg lycopene per 100g tomatoes; 1µg per 100g
carrots and 4,532 µg per 100g watermelon [130].
In general, there are two kinds of lycopene, trans-lycopene and cis-lycopene. Translycopene is its natural form that is long and straight while cis-lycopene is a bent form that
circulates in human blood. Trans-lycopene comprises 79-91% of total lycopene in tomato

20
and tomato products, while cis-lycopene makes up more than 50% of the total lycopene
in human plasma [131, 132]. Isomerization is a process that converts trans-isomers to cisisomers. Although the majority of isomerization is reported to occur in vivo, the mechanism
of converting trans-lycopene to cis-lycopene in serum and tissues is not clear [133]. Translycopene and cis-lycopene have similar chemical properties. There is no significant difference in antioxidant activity between trans-lycopene and cis-lycopene [134].
2.7. Mechanism of Lycopene
After absorption from the intestine, lycopene is primarily distributed in adipose tissue
(60-72%), liver (17-23%), and serum or plasma (5-6%) [135]. Although the mechanism of
different distribution of lycopene is unclear, the distribution varying in different tissue may
suggest different functions for different tissues [135]. Lycopene concentrations at different
adipose tissue sites (abdomen, buttock, and thigh) have positive correlations with serum
lycopene concentration [136]. As a natural antioxidant, lycopene can alleviate oxidative
stress induced in animal models [125, 126]. Dietary intake of tomatoes or purified lycopene
supplementation has also decreased the oxidative damages in humans [18, 19, 127 and
128]. In addition, animal experiments demonstrate that lycopene can significantly decrease pro-inflammatory cytokine and chemokine expression by inhibiting the TNFαmediated activation of the NF-κB signaling pathway in vitro and in vivo [20, 21]. Therefore,
alleviating oxidative stress and suppressing inflammation may be the main mechanisms
for the effects of lycopene [137]. Serum concentrations of lycopene were measured using
high-performance liquid chromatography with multi-wavelength photodiode-array absorbance detection [138].
Lycopene was found to reduce the risks of developing chronic diseases. For example,
since the first report that lycopene can reduce the incidence rate of prostate cancer in
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1995 [26], lycopene has been found to be inversely associated with breast, cervical, ovarian, liver and other organ site cancers [27]. In addition to tumor-suppressive activity,
lycopene is found to reduce the risks of developing other chronic diseases, such as cardiovascular diseases and cerebrovascular diseases. These studies can usually be divided
into dietary intake lycopene studies and serum lycopene studies. In general, studies based
on lycopene intake failed to detect a significant association between lycopene and cardiovascular diseases and cerebrovascular diseases [139-141]. Misclassification of dietary
lycopene intake may be an alternative explanation for the failure of these dietary studies
[142].
There were many studies which examined the associations between lycopene and
heart diseases. Kohlmeier and colleagues found that there was a dose-response inverse
association between lycopene and myocardial infraction with a population-based casecontrol study in Europe (EURAMIC Study) [28]. Karppi and colleagues also found that low
serum lycopene increased the risk of myocardial infarction in Finnish men [29]. However,
Hak and colleagues did not find an association between serum lycopene and the risk of
myocardial infarction in United States male physicians [65]. For coronary heart disease in
Czech, Bavarian and Israeli men, Bobak and colleagues found there was a significant
association between lycopene and coronary heart disease [30]. A cohort study (the Kuopio
Ischaemic Heart Disease Risk Factor Study) found that the lower level of serum lycopene
was associated with increased risks of coronary heart disease with 6 years of follow-up
for Finnish people [31].
For stroke, Rissanen and colleagues found low serum levels of lycopene was associated with an increased risk of stroke with 6 years of follow-up for Finnish people [31]. With
the same cohort data, Karppi and colleagues also found low serum levels of lycopene
continued to be associated with an increased risk of stroke with 12 years of follow-up [143].
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For the combination of disease conditions, Sesso and colleagues found that high levels of
plasma lycopene concentration can reduce the incidence rate of cardiovascular disease
in women [144]. However, Sesso and colleagues did not find that high plasma lycopene
concentration was associated with the risk of cardiovascular disease in older men [66].
In addition to reducing the risk of cardiovascular disease and cerebrovascular disease,
lycopene was found to improve endothelial function in participants with cardiovascular
disease [145]. Kristenson and colleagues found that the mortality from coronary heart disease in Lithuania was associated with serum concentration of lycopene [146]. Ito and
colleagues also reported that lycopene played an important role in preventing death from
cardiovascular diseases in Japanese patients [61]. However, Karppi and colleagues did
not find an association between the risk of cardiovascular disease mortality and serum
concentration of lycopene among Finnish men [67].
For all-cause mortality, with NHANES III data, Patel and colleagues found that serum
concentration of lycopene was negatively related to all-cause mortality [62]. However, with
the same data, Shardell and colleagues only found the middle two quartiles had an association with all-cause mortality while the lowest quartile and the highest quartile had no
association with all-cause mortality [147]. Furthermore, the authors found high serum concentration of lycopene up to 0.40 µmol/L was associated with a reduced mortality. Starting
at 0.50 µmol/L, a high serum concentration of lycopene was associated with increased
mortality (P<0.001). Therefore, the authors indicated that there may be a U-shaped relationship between serum lycopene and mortality [147].
2.8. Lycopene Measurement and Factors Associated with Lower Serum Lycopene
Usually, there are two methods for lycopene measurement: serum concentration of
lycopene and dietary intake of lycopene. Although most lycopene is distributed in adipose
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tissue [135], it is not common to test lycopene concentration in adipose tissue because it
is inconvenient to detect in these tissues. In addition, serum lycopene concentration has
a positive correlation with lycopene concentration in adipose tissue [136]. Therefore, serum or plasma lycopene is the common measure for humans. Lycopene concentration
can be measured in serum by reverse-phase high-performance liquid chromatography [33]
while dietary intake of lycopene can be estimated by using 24-hour food recalls (values
were converted to mg per day based on checklist of tomato-based foods) [34]. Serum
concentration of lycopene is an objective test measurement while dietary intake of lycopene is an subjective measurement of self-reported data. Therefore, serum concentration
of lycopene is more valid and reliable than dietary intake of lycopene [142].
Studies show that there are several factors related to high (or low) levels of serum
lycopene. For example, race/ethnicity, gender and age have associations with serum concentration of lycopene [148-150]. In addition, lifestyles can impact serum concentration of
lycopene. For example, cigarette smoking was inversely associated with serum concentration of lycopene [151]. The effects of alcohol consumption on serum concentration of
lycopene are inconsistent in previous reports [152, 153].
2.9. Lycopene Levels among Overweight and Obese Individuals
Individuals who are overweight or obese tend to have less healthy dietary habits. For
example, usually, overweight or obese individuals consume too much energy and consume much less fruits and vegetables [154, 155]. Lycopene is mainly contained in
tomatoes and other vegetables or fruits, such as red carrots and watermelons. These
findings suggest that serum lycopene levels are lower among overweight and obese individuals than normal weight individuals. However, there is not sufficient evidence to support
this notion. Two small sample studies found a lower level of lycopene among obese individuals compared to normal weight individuals but the difference was not statistically
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significant [36, 156]. To overcome the small sample size, the data based on the third
NHANES 1988-1994 (N=3,413) was used for studying the association between serum
concentration of lycopene and BMI status. The authors did not report results for serum
concentration of lycopene among normal weight, overweight and obese individuals but
they mentioned that BMI was not associated with serum lycopene in an multivariate adjusted regression analysis of serum lycopene concentration [149].
With the same dataset, Kimmons and colleagues found that the low serum lycopene
levels (20th percentile by age and gender as the cutoff) were inversely associated with
BMI for women and not for men [157]. Therefore, these inconsistent results may also contribute to the difference criteria for the definition of “high” and “low” serum concentration
of lycopene because no standard criteria exist for serum concentration of lycopene in the
body. Therefore, relative serum concentration of lycopene to the amount of oxidative
stress and/or inflammatory reaction is more rational for the definition of “high” or “low”
serum concentration of lycopene according to self-requirement in the body.
2.10. The Health Effects of Lycopene in Overweight and Obese Adults
Overweight and obese individuals have an increased risk of developing metabolic syndrome due to subsequent chronic inflammation and oxidative stress [11, 12, 99 and 100].
Alleviating oxidative stress and suppressing inflammation are the main mechanisms for
the effects of lycopene [137]. Therefore, lycopene has the potential to reduce the risk of
metabolic syndrome by suppressing inflammation and oxidative stress in overweight and
obese individuals.
The health effects of lycopene on reducing inflammation and oxidative stress remain
inconsistent in overweight and obese adults. For example, Yeon et al., McEneny et al. and
Ghavipour et al. found that lycopene intervention can significantly reduce inflammation
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and oxidative stress in overweight and obesity participants [32-34], while Markovits et al.
and Thies et al. did not find a significant association between inflammation and oxidative
stress and lycopene [36, 37]. Therefore, health effects of lycopene for individuals who are
overweight and obese are still controversial.
One of the potential reasons for the varying effects of lycopene is differences in the
amount of serum lycopene in these studies. For example, in participants who were of
similar race, age range, and BMI status, greatly increased concentrations of lycopene
(1140 umol/L) significantly affected inflammation and/or oxidative stress [33], while a small
increase in the cncentration of lycopene (7.61 umol/L) did not have significant effects [37].
Therefore, health effects of serum lycopene may also depend on the serum concentration
of lycopene.
Another point to consider when interpreting the research findings on lycopene is variations in the levels of oxidation and inflammation in different individuals. For example,
based on equal serum concentrations of lycopene, it is possible that only in participants
who have a lower BMI, lycopene can effectively reduce the levels of TNF-α and IL-8 and
increase the levels of superoxide dismutase, glutathione peroxidase and catalase, and
total antioxidant capacity of plasma [34, 35]. The same “high” serum concentrations of
lycopene for individuals with a lower BMI status do not produce significant health effects
for individuals with a higher BMI status due to increased inflammation and oxidative stress
production [34, 35]. Therefore, health effects of serum lycopene appear to depend on the
amount of inflammation and/or oxidative stress in the body.
Taken together, health effects of serum lycopene depend not only on serum concentration of lycopene, but also on the amount of inflammation and/or oxidative stress in the
body. Therefore, we hypothesized that the ratio of serum concentration of lycopene to the
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amount of inflammation and/or oxidative stress could better predict health effects of serum
lycopene than with only the serum concentration of lycopene.
2.11. Summary
In this chapter, we first reviewed overweight/obesity, inflammation/oxidative stress and
metabolic syndrome. Then we reviewed nutrient intake for prevention of metabolic syndrome, especially for lycopene. Accumulative evidence supports that lycopene can reduce
the risk of metabolic syndrome and chronic disease. Alleviating oxidative stress and suppressing inflammation are the main mechanisms for the effects of lycopene. However, the
health effects of lycopene on reducing inflammation and oxidative stress remain inconsistent in overweight and obese adults. These inconsistent results may be due to different
serum concentrations of lycopene or different amounts of inflammation and/or oxidative
stress in the participants’ body. We hypothesized that the ratio of serum lycopene to the
amount of inflammation and/or oxidative stress may be a better measure for analysis of
health effect of lycopene than with only the serum concentration of lycopene.
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CHAPTER 3 RESEARCH METHODS
3.1. Overview
This is a secondary analysis of data from a population-based cross-sectional survey
conducted in the United States. This study used publicly available NHANES data. The
NHANES 2001–2006 data included 15,431 participants who were at least 20 years old
(7,341 men and 8,090 women). The outcome variables were metabolic syndrome and
mortality. The exposure variables included serum concentration of lycopene, the ratio of
serum lycopene to serum triglyceride and physical activity. Chi-square tests, multivariate
logistic regressions and Cox models were used in association analyses.
3.2. NHANES
The NHANES is conducted by the National Center for Health Statistics of the CDC to
assess the health and nutrition conditions of adults and children in the United States. We
used the 2001-2006 NHANES data. The study samples included all participants aged 20
years and older. There were 5,411 adult participants in 2001-2002, 5,041 in 2003-2004
and 4,979 in 2005-2006. Individuals were excluded if they had missing information for
classification of metabolic syndrome and serum concentration of lycopene. For an analysis of the additive effect of physical activity and lycopene, individuals were excluded if they
had missing information for physical activity. For a mortality analysis, individuals were excluded if they had diabetes, heart diseases and stroke history or if their underlying causes
of death were from these conditions. Using a multistage, stratified sampling design, the
NHANES obtains a representative sample of civilian, non-institutionalized individuals in
the United States. In the first sample stage, researchers selected the primary sampling
units (PSUs) from the sampling frame including all counties in the United States with PPS
(probabilities proportionate to the measure of size) sample technique. PPS means that the
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likelihood of being selected is proportionate to the size of the unit. In the second sample
stage, researchers selected the segments from the sample frame including all census
blocks or combined blocks in the selected PSUs in the first sample stage with PPS technique. In the third sample stage, researchers selected dwelling units (DUs) from the
sample frame including all non-institutional group quarters in the selected segments in the
second sample stage. To obtain reliable estimates of health and nutritional measures,
oversampling for some subgroup populations were designed in this stage. For example,
non-Hispanic African Americans and Mexican Americans were oversampled during 20012006. In the fourth sample stage, researchers selected individuals from the list within DUs
or households based on a previously defined probability for different race, income, gender
and age groups [138, 158].
Data collections include home interviews and examinations in NHANES survey. The
NHANES home interviews included demographic, socioeconomic, dietary, and health-related questions. A trained household interviewer administered the questionnaires in the
sample participant’s home. The interview was conducted using a computer-assisted personal interview system and Blaise software [138, 158]. The NHANES examinations took
place in the mobile examination center (MEC). The examination component consists of
medical, dental, and physiological measurements, as well as laboratory tests administered
by highly trained medical personnel. Eligibility for examination components was determined by the participant’s age and gender. The controlled environment of the MEC
allowed physical measurements to be done under identical conditions at each survey location [138, 158].
3.3. Mortality Follow-Up
The NHANES 2001-2006 Linked Mortality File provided mortality information for participants involved in NHANES interview (2001-2006) through December 31, 2011. The
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method of probabilistic linkage was used to trace NHANES participants with the National
Death Index (NDI) for vital status. The linkage between survey participants and NDI can
provide important information to conduct outcome studies, for example, in this study, the
association between serum lycopene and mortality and the possible additive effect of
physical activity and lycopene on mortality.
3.4. Study Samples
The sample for Aim 1 consisted of a total of 13,196 participants from the 2001-2006
NHANES. Figure 2 shows how this sample was derived and categorized into three groups
according to the serum lycopene concentration. Of the 15,431 participants of the NHANES
2001-2006, a total of 2,235 were excluded due to missing information on metabolic syndrome (n=1,011), BMI (n=477), and serum lycopene concentration (n=747).
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Figure 2. Aim 1 sample flow chart
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The sample for Aim 2 consisted of a total of 13,154 participants from the 2001-2006
NHANES. Figure 3 shows how this sample was derived and categorized into three groups
according to the ratio of serum concentration of lycopene to serum concentration of triglyceride. Of the 15,431 participants of the NHANES 2001-2006, a total of 2,277 were
excluded due to missing information on metabolic syndrome (n=1,011), BMI (n=477), serum lycopene concentration (n=747), and serum triglyceride concentration (n=42).
Figure 3. Aim 2 sample flow chart
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The sample for Aim 3 consisted of 2,496 participants from the 2001-2006 NHANES
(Figure 4). Of the 3,868 participants with metabolic syndrome of the NHANES 2001-2006,
a total of 1,372 were excluded due to missing information on serum lycopene concentration (n=170) and serum triglyceride concentration (n=5) or due to a history of diabetes or
heart disease or stroke (n=1,130) or due to underlying causes of death for diabetes or
heart disease or stroke (n=67).
Figure 4. Aim 3 sample flow chart
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The sample for Aim 4 consisted of a total of 9,038 participants from the 2001-2006
NHANES. Figure 5 shows how this sample was derived and categorized into three groups
according to the ratio of serum concentration of lycopene to serum concentration of triglyceride or physical activity statues. Of the 9,604 participants (BMI≥25) of the NHANES
2001-2006, a total of 566 were excluded due to missing information on serum lycopene
concentration (n=537), serum triglyceride concentration (n=26), and physical activity (n=3).
Figure 5. Aim 4 sample flow chart
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The sample for Aim 5 consisted of 2,495 participants from the 2001-2006 NHANES
(Figure 6). Of the 3,868 participants with metabolic syndrome of the NHANES 2001-2006,
a total of 1,373 were excluded due to missing information on serum lycopene concentration (n=170), serum triglyceride concentration (n=5) and physical activity (n=1) or due to
history with diabetes or heart disease or stroke (n=1,130) or due to underlying causes of
death for diabetes or heart disease or stroke (n=67).
Figure 6. Aim 5 sample flow chart
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3.5. Measurements
3.5.1. Metabolic syndrome assessment and classification
The guideline provided in the National Cholesterol Education Program’s Adult Treatment Panel III report was used to identify individuals with metabolic syndrome. To be
diagnosed with metabolic syndrome, an individual has to meet three or more of the following criteria: abdominal obesity (waist circumference >40 inches for men and >35 inches
for women); hypertriglyceridemia (serum triglyceride ≥1.69 mmol/L); low HDL-cholesterol
(HDL <1.04 mmol/L for men and <1.29 for women); hypertension (≥130/85 mmHg) and
high fasting glucose (fasting glucose ≥6.1 mmol/L) [2]. In this study, waist circumference
(BMXWAIST), serum triglyceride (LBDSTRSI), serum HDL-cholesterol (LBDHDDSI), systolic blood pressure/ diastolic blood pressure and fasting glucose (LBDGLUSI) were used
for classification of metabolic syndrome.
3.5.2. BMI assessment and classification
Overweight and obesity are conditions of excess fat accumulation in the body. BMI,
an expression with weight divided by height squared (kg/m2), is a common measure for
classification of overweight and obesity. An adult with a BMI less than 24.9 kg /m2 is considered to be normal weight; an adult with a BMI between 25.0 and 29.9 kg /m2 is
considered to be overweight and an adult with a BMI of 30 kg/m2 or higher is considered
to be obese.
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3.5.3. Lycopene assessment and classification
Serum concentration of trans-lycopene was measured using high-performance liquid
chromatography with multi-wavelength photodiode-array absorbance detection. Serum triglyceride was measured enzymatically by using a series of coupled reactions by Hitachi
717 analyzer [70].
For dietary measurement, NHANES collected two 24-hour dietary recalls for every
participant by using the United States Department of Agriculture (USDA)’s Automated
Multi-Pass Method. The first 24-hour recall was conducted at the MEC; the second 24hour recall was conducted by telephone 3-10 days later. Four data files were created from
dietary interview information: two individual foods files and two total nutrient intake files.
The individual foods data files include information about the types and amounts of individual foods, as well as amounts of nutrients from each food. The nutrient amounts in the
total nutrient intake files only reflect nutrients acquired from foods and beverages reported
by participants. The nutrient amounts in the total nutrient intake files do not include nutrients from dietary supplements, medications, or plain drinking water. For example, total
dietary lycopene only reflects intake from foods and beverages and not including any from
dietary supplements and medications [138].
3.5.4. Physical activity assessment and classification
Physical activity was categorized into no physical activity, moderate physical activity
and heavy physical activity. The categories of physical activity were defined based on the
two questions: (1) “Over the past 30 days, did you do any vigorous activities for at least
10 minutes that caused heavy sweating, or large increases in breathing or heart rate?”
and (2) “Over the past 30 days, did you do moderate activities for at least 10 minutes that
cause only light sweating or a slight to moderate increase in breathing or heart rate?” If
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the answer to the first questions was “Yes”, participants were classified as “Heavy physical
activity”. If the answer to the second question was “Yes” and the answer to the first question was anything other than “Yes”, participants were classified as “Moderate physical
activity”. If the answers to both questions were “No” or “Unable to do activity”, participants
were classified as “No physical activity”.
3.5.5. Alcohol consumption assessment and classification
Alcohol consumption values were categorized based on two questions: (1) “Have you
had at least 12 alcohol drinks/1 year?” and (2) “In the past 12 months, on those days that
you drank alcoholic beverages, on the average, how many drinks did you have per day?”
If the answer to the first question was “No”, participants were classified as “No alcohol
consumption”. The alcohol consumption level was classified as “Moderate alcohol consumption” if the participant answered “Yes” to the first question and “Average alcoholic
drinks/per day less than or equate to 2 for men and less than or equate to 1 for women”
to the second question; the alcohol consumption level was classified as “Heavy alcohol
consumption” if the participant answered “Yes” to the first question and “Average alcoholic
drinks/per day more than 2 for men and more than 1 for women” to the second question.
3.5.6. Smoking assessment and classification
Smoking status was categorized based on three questions: (1) “Have you smoked at
least 100 cigarettes in your entire life?” (2) “Do you now smoke cigarettes?” and (3) “During the past 30 days, on the days that you smoked, about how many cigarettes did you
smoke per day?” If the answer to the first question was “No”, participants were classified
as “No smoker”; If the answer to the first question was “Yes” and the answer to the second
question was “Not at all”, participants were classified as “Past smoker”. Smoking status
was classified as “Current smoker” if the participant answered “Yes” to the first question
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and “Every day or some days” to the second question and “Average more than 1 cigarette
/per day” to the third question.
3.5.7. Assessment and classification of other variables of interest
In this study, demographic variables included race/ethnicity (Non-Hispanic White,
Non-Hispanic Black, Mexican American and others), gender (Male and Female), and age
group (20–39, 40–59 and ≥60 years). Common chronic disease conditions included diabetes, heart disease, stroke, cancer. Diabetes was defined as answering “Yes” to the
question “Whether a doctor told you that you had diabetes?”; and heart disease was defined answering “Yes” to any of the following three questions “Has a doctor told you that
you had coronary heart disease?” or “Has a doctor told you that you had angina/angina
pectoris?” or “Has a doctor told you that you had heart attack?”; and stroke was defined if
the participant answered “Yes” to the question “Has a doctor told you that you had stroke?”
Cancer or malignancy was defined as answering “Yes” to the question “Has a doctor told
you that you had cancer or a malignancy of any kind?”
3.6. Missing Data
The main purpose of this study was to examine the associations between serum lycopene and metabolic syndrome or mortality. Therefore, the accuracy was very important
for this study. Imputing a value for the missing data, such as serum concentration of lycopene, could potentially introduce inaccurate values into the data. Therefore, we did not
choose to impute a value for the missing data. We compared the sample characteristics
between the original and the final samples. The percent of men was 47.6% in the original
sample (15,431) and 48.0% in the final sample (13,196). The percent was 36.2% for participants aged 20-39 years, 29.2% for participants aged 40-59 years and 34.6% for
participants aged 60 years and older in the original sample; the percent was 36.8% for
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participants aged 20-39 years, 30.4% for participants aged 40-59 years and 33.8% for
participants aged 60 years and older in the final sample. The prevalence of metabolic
syndrome was 26.8% in the original sample and 27.2% in the final sample. Therefore,
after excluding the participants with missing information, the sample characteristics did
not change.
3.7. Statistical Analyses
3.7.1. Survey weights
Statistical analyses were performed using SAS Survey Procedures (i.e., proc surveyfreq and proc surveymeans) to take into account the survey clusters, strata and
weights (SAS version 9.3, SAS Institute, Cary, NC, USA). The weighting of sample data
was used to produce estimates of the statistics they would have obtained if the entire
sampling frame had been surveyed. Therefore, in order to make valid statistical inferences
for the parameters of the population, statistical analyses in this study were taken into account the survey clusters, strata and weights.
A non-simple random sample may not represent the general population. As a complex
multistage sample design, NHANES is a non-simple random sample. In addition, there
are some other issues, such as non-response and non-coverage of the population in this
study. If we estimate the population parameter with the non-weighted sample, we will get
a biased estimation because the sample does not represent the target population. Therefore, to make sure that a sample is representative of the target population, we should
calculate weights for all sample units. Then, we can get an unbiased estimate for this
population after incorporating the weights in estimating the population parameter with
sample [138, 158].
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There were mainly two sample weights in NHANES for use; one was sample weights
for in-home interview and another was sample weights for MEC exam. According to the
rule “least common denominator” approach, we needed to select MEC exam sample
weights because MEC exam sample weights had the least common denominator. Second,
we needed to construct the combined sample weights for combined multi-year samples.
We constructed the combined sample weights because we combined the samples from
2001 to 2006 in this study. The combined sample weights= 1/3 * original sample weights
(for 01-02, 03-04 and 05-06 survey cycles). Third, we needed to take into account of cluster and strata design. For variance estimation, we also needed to take into account of
cluster and strata for design in this study for unbiased estimation of variance with SAS
survey procedures. Fourth, we needed to take into account of subsample analysis in the
study; for example, we only analyzed the data for obesity and overweight adult participants. For proper estimation of variance, we needed to produce a variable for obesity and
overweight adult participants=1, others=0; then use DOMAIN statements in the SAS survey procedure [160].
3.7.2. Statistical analysis methods
For Aim 1, chi-square tests were used to examine the associations between metabolic
syndrome and race/ethnicity, gender, age and BMI status. The mean and standard deviation (SD) were used for estimating serum concentration of lycopene. In addition, logistic
regression models were performed to evaluate the association between the prevalence of
metabolic syndrome and serum concentration of lycopene and to calculate the odds ratios
(ORs) and 95% Confidence Intervals (CIs) after adjusting for race, gender, age group,
alcohol consumption, smoking and physical activity.
For Aim 2, chi-square tests were used to examine the associations between metabolic
syndrome and race/ethnicity, gender, age and BMI status. The mean and SD was used
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for estimating the ratio of serum concentration of lycopene to serum concentration of triglyceride. In addition, logistic regression models were performed to evaluate the
association between the prevalence of metabolic syndrome and the ratio of serum concentration of lycopene to serum concentration of triglyceride and to calculate the ORs and
95% CIs after adjusting for race, gender, age group, alcohol consumption, smoking and
physical activity.
For Aim 3, chi-square tests were used to examine the associations between the ratio
of serum concentration of lycopene to serum concentration of triglyceride and race/ethnicity, gender, age group, BMI status, alcohol consumption, smoking status and physical
activity. Chi-square tests were also used to examine the associations between the ratio of
serum concentration of lycopene to serum concentration of triglyceride and mortality and
disease-specific mortality. In addition, a Cox model was performed to evaluate the hazard
ratios (HRs) and 95% CI of mortality for the ratio of serum concentration of lycopene to
serum concentration of triglyceride adjusting for race/ethnicity, gender, age group, BMI
status, alcohol consumption, smoking status, physical activity and cancers. Backward procedure was performed for model selection.
For Aim 4, physical activity levels were categorized into no physical activity, moderate
physical activity and heavy physical activity. Chi-square tests were used to examine the
associations between physical activity and the prevalence of metabolic syndrome. To examine the effects of serum lycopene on the prevalence of metabolic syndrome,
participants were divided into three groups by tertile ranking method according to the ratio
of serum lycopene to serum triglyceride. Chi-square tests were used to examine the associations between serum lycopene levels (first tertile group, second tertile group and third
tertile group) and the prevalence of metabolic syndrome. To investigate the additive effect
of physical activity and lycopene level on the prevalence of metabolic syndrome, Chi-
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square tests were used—the tests examined the associations between all combinations
between physical activity (no physical activity, moderate physical activity and heavy physical activity) and serum lycopene levels (first, second, and third tertile groups) and the
prevalence of metabolic syndrome for each of the BMI group. In addition, logistic regression models were performed to evaluate the associations between physical activity, serum
lycopene levels and the prevalence of metabolic syndrome for each of the BMI group.
ORs and 95% CIs were calculated after adjusting for race, gender, age group, alcohol
consumption, and smoking status. The mean ratio of serum lycopene to serum triglyceride
by physical activity was also estimated.
For Aim 5, to examine the effect of physical activity on mortality, chi-square tests were
used to examine the association between physical activity (no physical activity, moderate
physical activity and heavy physical activity) and mortality. To examine the effects of serum lycopene on mortality, participants were divided into three groups by tertile ranking
method according to the ratio of serum lycopene to serum triglyceride. Chi-square tests
were used to examine the association between serum lycopene levels and mortality. To
investigate the additive effect of physical activity and lycopene level on mortality, Chisquare tests were used to examine the associations between physical activity, serum lycopene levels and mortality. In addition, a Cox model was performed to evaluate the
hazard ratios (HRs) and 95% CIs after adjusting for race, gender, age group, alcohol consumption, smoking status. The mean ratio of serum lycopene to serum triglyceride by
physical activity was also estimated.
Statistical analyses were adjusted for clusters and strata of the complex sample design
of the NHANES 2001-2006, using sample weights for aim 1, 2 and 4. Statistical analyses
were not adjusted for clusters and strata of the complex sample de-sign of the NHANES
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2001-2006, using sample weight for aim 3 and 5. A two-sided P-value < 0.05 was considered to be statistically significant for all statistical analysis.
3.8. Assumptions of the Study
We assumed that all participants truthfully responded to the survey questions. We also
assumed that serum concentration of lycopene and serum concentration of triglyceride
did not change from the interview (2001-2006) to death or December 31, 2011. In addition,
serum samples, such as serum concentration of lycopene and serum concentration of
triglyceride, were only available at baseline; we cannot estimate the effect of changes of
serum lycopene and serum triglyceride on the risk of mortality over time because of the
cross-sectional design of NHANES 2001-2006.
3.9. Summary
The study belonged to the population-based cross-sectional study design because the
data for this study came from the NHANES. The combination of NHANES 2001–2006
included 15,431 participants who were at least 20 years of age (7,341 men and 8,090
women). The main outcomes were the prevalence of metabolic syndrome and mortality.
The main exposures were serum concentration of lycopene or the ratio of serum lycopene
to serum triglyceride. Statistical analyses in this study were performed using SAS Survey
Procedures (i.e., proc surveyfreq and proc surveymeans) to take into account of survey
clusters, strata and weights.
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CHAPTER 4 RESEARCH FINDINGS
4.1. The Influence of BMI on the Association between Serum Lycopene and the
Prevalence of Metabolic Syndrome
4.1.1. Demographic characteristics, BMI status, and serum lycopene level of adults with
metabolic syndrome and those without metabolic syndrome
Of the 13,196 participants, 3,601 (27.3%) had a diagnosis of metabolic syndrome. The
prevalence of each metabolic syndrome condition was the following: abdominal obesity
(50.3%; 95% CI: 48.7-51.9) hypertriglyceridemia (32.4%; 95% CI: 31.2-33.5), low HDLcholesterol (32.4%; 95% CI: 31.2-33.5), hypertension (30.8%; 95% CI: 29.5-32.0), and
high fasting glucose (18.3%; 95% CI: 16.9-19.6). Demographic characteristics, the BMI
status, and the serum lycopene level of adults with metabolic syndrome and those without
metabolic syndrome are presented in Table 1. Individuals with metabolic syndrome tended
to be older than those without metabolic syndrome. For example, 46.8% of those with
metabolic syndrome were from the oldest age group (≥60 years) compared to 27.3% for
those without metabolic syndrome. There was a significant difference in racial/ethnic characteristics between these two groups. For example, the metabolic syndrome group had a
higher proportion of Mexican Americans than the non-metabolic syndrome group (23.4%
vs. 19.7%). The percent of metabolic syndrome was substantially increased with increased BMI. Less than 10% of individuals in the metabolic syndrome group were
classified as having a normal weight while about 40% of the non-metabolic syndrome
group were in that category. Conversely, close to 60% of the metabolic group were in the
obese category while about 20% of the non-metabolic group were in that category. The
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mean of serum concentration of lycopene was significantly lower in participants with metabolic syndrome than participants without metabolic syndrome (0.38 umo/L vs. 0.42
umo/L).
Table 1. Demographic characteristics, BMI status, and serum lycopene level of adults with
metabolic syndrome and those without metabolic syndrome
Variable
Metabolic Syndrome No Metabolic Syndrome P-value
(N=3,601)
(N=9,595)
N
% or
N
% or
Mean (SD)
Mean (SD)
Age (years)
20-39
698
19.4
4,170
43.5
<0.0001
40-59
1,219
33.9
2,799
29.2
≥ 60
1,684
46.8
2,626
27.3
Sex
Male
1,720
47.8
4,615
48.1
0.0897
Female
1,881
52.2
4,980
51.9
Race
NH White
1,978
54.9
4,912
51.2
<0.0001
NH African Ameri550
15.3
2,065
21.5
can
Mexican American
844
23.4
1,887
19.7
Other
229
6.4
731
7.6
BMI group
Normal weight
276
7.7
3,853
40.2
<0.0001
Overweight
1,258
34.9
3,461
36.1
Obese
2,067
57.4
2,281
23.7
Serum lycopene
3,601
0.38 (0.20)
9,595
0.42 (0.21)
<0.0001
(umol/L)
NH: Non-Hispanic; N: number; SD: standard deviation.

4.1.2. Interaction between Serum Lycopene Concentration and BMI Status
The mean of serum concentration of lycopene was significantly lower in participants
with metabolic syndrome than participants without metabolic syndrome. The mean serum
concentration of lycopene was 0.206 umol/L (95% CI: 0.203-0.209) for the first tertile
group, 0.387 umol/L (95% CI: 0.385-0.389) for the second tertile group and 0.642 umol/L
(95% CI: 0.635-0.648) for the third tertile group. The prevalence of metabolic syndrome
was significantly higher in the first tertile group [31.5% (95% CI: 29.9-32.9)] compared with
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the second tertile group [25.5% (95% CI: 23.9-27.2)] and the third tertile group [22.9% (95%
CI: 21.4-24.3)]. Table 2 shows the results of a multivariate logistic analysis. After adjusting
for race, gender, age, alcohol consumption, smoking, physical activity and BMI status,
there was still a significant association between metabolic syndrome and the levels of
serum lycopene. Most importantly, there was a significant interaction effect between serum lycopene and BMI status on metabolic syndrome (p<0.0001).
Table 2. A multivariate logistic model for the association between the prevalence of metabolic syndrome and serum levels of lycopene
Effect
DF
Wald Chi-Square
P-value
Race
3
165.19
<.0001
Gender
1
8.10
0.0044
Age group
2
252.45
<.0001
Alcohol consumption
2
30.95
<.0001
Smoking status
2
19.23
<.0001
Physical activity
2
57.22
<.0001
Serum lycopene
2
21.58
<.0001
BMI
2
1370.15
<.0001
Serum lycopene* BMI
4
31.90
<.0001
DF: degree of freedom; BMI: body mass index.

4.1.3. Stratification by BMI Status
BMI is an effect modifier of the association between serum lycopene and metabolic
syndrome. With an effect modification, a stratified analysis is an appropriate method to
examine the association between exposure and outcome. Figure 7 shows the associations
between serum lycopene and metabolic syndrome stratified by BMI status. For normal
weight participants, the prevalence of metabolic syndrome was significantly lower in the
third tertile group [3.2%, 95% CI: 2.1-4.3] compared to the first tertile group [9.8%, 95%
CI: 7.9-11.8], and also the prevalence of metabolic syndrome was significantly lower in
the second tertile group [3.8%, 95% CI: 2.6-4.9] compared to the first tertile group [9.8%,
95% CI: 7.9-11.8]. For overweight participants, the prevalence of metabolic syndrome was
significantly lower in the third tertile group [20.9%, 95% CI: 18.6-23.3] compared to the
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first tertile group [32.2%, 95% CI: 29.3-35.0] and also the prevalence of metabolic syndrome was significantly lower in the second tertile group [25.0, 95% CI: 22.8-27.2]
compared to the first tertile group [32.2%, 95% CI: 29.3-35.0]. However, for obese participants, there was no significant difference of the prevalence of metabolic syndrome among
the first tertile group [49.9%, 95% CI: 47.5-52.3], the second tertile group [50.1%, 95% CI:
46.5-53.6] and the third tertile group [47.6%, 95% CI: 44.3-51.0].
Figure 7. The association between metabolic syndrome and serum concentration of lycopene stratified by BMI status

BMI: body mass index
a The prevalence of metabolic syndrome was significantly different (p<0.05) between the 1st and 2nd tertiles
for BMI<24.9.
b The prevalence of metabolic syndrome was significantly different (p<0.05) between the 1st and 3rd tertiles
for BMI<24.9.
c The prevalence of metabolic syndrome was significantly different (p<0.05) between the 1 st and 2nd tertiles
for BMI:25-29.9.
d The prevalence of metabolic syndrome was significantly different (p<0.05) between the 1st and 3rd tertiles for
BMI:25-29.9.
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After adjusting for race, gender, age, alcohol consumption, smoking and physical activity, the associations between metabolic syndrome and serum levels of lycopene
remained significant for participants who were normal weight or overweight (Table 3).
Table 3. Multivariate logistic models for the associations between the prevalence of metabolic syndrome and serum levels of lycopene by BMI status
Serum Lycopene
BMI
1st Tertile
2nd Tertile
3rd Tertile
OR
OR*
95% CI
OR*
95% CI
0.56
0.51
<24.9
1
(0.34-0.90)
(0.31-0.85)
0.76
25-29.9
1
0.92
(0.76-1.11)
(0.59-0.97)
≥30
1
1.07
(0.90-1.28)
1.03
(0.87-1.22)
BMI: body mass index; OR: odds ratio; CI: confidence interval; *: Adjusted for race, gender, age, alcohol
consumption, smoking and physical activity

4.1.4. Stratification by serum levels of lycopene and BMI status
We compared the mean serum concentration of lycopene and serum concentration of
triglyceride by serum lycopene and BMI status. Table 4 shows the mean of serum concentration of lycopene and serum concentration of triglyceride stratified by serum levels
of lycopene and BMI status. For normal weight participants, the mean serum concentration
of lycopene was significantly higher in the third tertile group (0.63 umol/L) when compared
to the first tertile group (0.20 umol/L). However, there was no significant difference of serum concentration of triglyceride between the third tertile group (1.20mmol/L) and the first
tertile group (1.33mmol/L). For overweight participants, the mean serum concentration of
lycopene was significantly higher in the third tertile group (0.65 umol/L) when compared
to the first tertile group (0.21 umol/L). There was no significant difference of serum concentration of triglyceride between the third tertile group (1.88mmol/L) and the first tertile
group (1.77mmol/L). For obese participants, the mean serum concentration of lycopene
was significantly higher in the third tertile group (0.64 umol/L) when compared to the first
tertile group (0.21 umol/L). Also, the serum concentration of triglyceride was significantly
different between the third tertile group (2.08mmol/L) and the first tertile group
(1.83mmol/L).
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Table 4. The mean of serum concentration of lycopene and serum concentration of triglyceride stratified by serum levels of lycopene
and BMI status
BMI
Tertile

1st

2nd

3rd

Label
Lycopene
(umol/L)
Triglycerides
(mmol/L)
Lycopene
(umol/L)
Triglycerides
(mmol/L)
Lycopene
(umol/L)
Triglycerides
(mmol/L)

<24.9

≥30

25.0-29.9

N

Mean

95% CI

N

Mean

95% CI

N

Mean

95% CI

1,307

0.20

(0.19-0.20)

1,547

0.21

(0.20-0.21)

1,534

0.21

(0.21-0.22)

1,298

1.33

(1.17-1.48)

1,540

1.77

(1.67-1.87)

1,528

1.83

(1.74-1.92)

1,411

0.39

(0.38-0.39)

1,546

0.39

(0.38-0.39)

1,453

0.39

(0.39-0.39)

1,407

1.14

(1.10-1.18)

1,542

1.63

(1.56-1.70)

1,451

2.04

(1.91-2.17)

1,411

0.63

(0.62-0.64)

1,626

0.65

(0.64-0.66)

1,361

0.64

(0.63-0.65)

1,408

1.20

(1.16-1.25)

1,621

1.88

(1.74-2.01)

1,359

2.08

(1.98-2.19)

N: number; BMI: body mass index; CI: confidence interval.
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4.2. An Association between the Lycopene to Triglyceride Ratio and the Prevalence of Metabolic Syndrome
4.2.1. Demographic characteristics, BMI status, and the ratio of serum lycopene to serum triglyceride of adults with metabolic syndrome and those without metabolic
syndrome
Of the 13,154 participants, 3,596 (27.3%) had a diagnosis of metabolic syndrome.
Table 5 shows the demographic characteristics, BMI status, and serum lycopene level of
adults with metabolic syndrome and those without metabolic syndrome. Individuals with
metabolic syndrome tended to be older than those without metabolic syndrome. For example, 46.7% of those with metabolic syndrome were in the oldest age group (≥60 years)
compared to 27.3% for those without metabolic syndrome. There was a significant difference in racial/ethnic characteristics between these two groups. For example, the
metabolic syndrome group had a higher proportion of Mexican Americans than the nonmetabolic syndrome group (23.4% vs. 19.7%). The percent of metabolic syndrome was
substantially higher among overweight and obese individuals compared to those with a
normal weight. Less than 10% of the individuals with metabolic syndrome were classified
as having a normal weight while about 40% of the non-metabolic syndrome group were in
that category. Conversely, close to 60% of the metabolic group were in the obese category
while about 20% of the non-metabolic groups were in that category. The mean ratio of
serum concentration of lycopene to serum concentration of triglyceride was significantly
lower in participants with metabolic syndrome than participants without metabolic syndrome.
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Table 5. Demographic characteristics, BMI status, and the ratio of serum lycopene to serum triglyceride of adults with metabolic syndrome and those without metabolic syndrome
Metabolic Syndrome No Metabolic Syndrome
(N=3,596)
(N=9,558)
Variable
P-value
% or
% or
N
N
Mean (SD)
Mean (SD)
Age (years)
20-39
697
19.4
4,158
43.5
40-59
1,219
33.9
2,789
29.2
<0.0001
≥60
1,680
46.7
2,611
27.3
Sex
Male
1,718
47.8
4,599
48.1
0.0925
Female
1,878
52.2
4,959
51.9
Race
NH White
1,975
54.9
4,893
51.2
NH African Ameri549
15.3
2,054
21.5
can
<0.0001
Mexican American
843
23.4
1,883
19.7
Other
229
6.4
728
7.6
BMI group
Normal weight
276
7.7
3,837
40.1
Overweight
1,254
34.9
3,449
36.1
<0.0001
Obese
2,066
57.5
2,272
23.8
Ratio of serum lycopene to serum
3,596
0.20 (0.16)
9,558
0.42 (0.31)
<0.0001
triglyceride
NH: Non-Hispanic; N: number; SD: standard deviation.

4.2.2. An association between the ratio of serum lycopene to serum triglyceride and the
prevalence of metabolic syndrome
The mean ratio of serum lycopene to serum triglyceride was significantly lower in individuals with metabolic syndrome than individuals without metabolic syndrome. To further
estimate the association between the prevalence of metabolic syndrome and the ratio of
serum lycopene to serum triglyceride, three groups of participants were divided by tertile
rank method according to the ratio of serum lycopene to serum triglyceride. The mean
ratio of serum lycopene to serum triglyceride was 0.12 (95% CI: 0.12-0.12) for the first
tertile group, 0.28 (95% CI: 0.28-0.29) for the second tertile group and 0.67 (95% CI: 0.660.68) for the third tertile group.

52
The prevalence of metabolic syndrome was significantly higher in the first tertile group
[52.7% (95% CI: 50.9-54.5)] compared to the second tertile group [24.7% (95% CI: 23.126.4)] and the third tertile group [7.0% (95% CI: 5.9-8.1)]. To adjust for possible confounding effects, a multivariate logistic analysis was performed to evaluate the associations
between the prevalence of metabolic syndrome and the ratio of serum lycopene to serum
triglyceride (Table 6). After adjusting for race, gender, age, alcohol consumption, smoking,
physical activity and BMI status, there was still a significant association between metabolic
syndrome and the ratio of serum lycopene to serum triglyceride.
Table 6. A multivariate logistic model for the associations between the prevalence of metabolic syndrome and the ratio of serum lycopene to serum triglyceride
Effect
DF
Wald Chi-Square
P-value
Race
3
56.64
<.0001
Gender
1
1.55
0.2135
Age group
2
109.83
<.0001
Alcohol consumption
2
15.61
0.0004
Smoking status
2
2.82
0.2437
Physical activity
2
16.27
0.0003
Ratio of Serum lycopene to serum
2
425.04
<.0001
triglyceride
BMI
2
546.44
<.0001
Ratio of Serum lycopene to serum
4
16.216
0.0027
triglyceride *BMI
DF: degree of freedom; BMI: body mass index.

4.2.3. Stratification by BMI status
To study the effect of the ratio of serum lycopene to serum triglyceride on the prevalence of metabolic syndrome among obese participants, associations between the ratio of
serum lycopene to serum triglyceride and metabolic syndrome were examined with a stratified analysis by BMI status (Figure 8). For each BMI status, there was a significant
difference in the prevalence of metabolic syndrome based on the ratio of serum lycopene
to serum triglyceride. For example, within the normal weight group, the prevalence of metabolic syndrome was the significantly higher among individuals in the first tertile group
[19.7%, 95% CI: 16.2-23.2] compared to the second tertile group [4.6%, 95% CI: 3.3-5.8].
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Similarly, the prevalence of metabolic syndrome was significantly higher among the second tertile group compared to the third tertile group [0.6%, 95% CI: 0.2-1.0]. The same
types of significant trends were observed for other BMI groups as well.
Figure 8. The association between metabolic syndrome and the ratio of serum lycopene
to serum triglyceride stratified by BMI status

BMI: body mass index;
a The prevalence of metabolic syndrome was significantly different (p<0.05) between the 1st and 2nd tertiles
for BMI<24.9.
b The prevalence of metabolic syndrome was significant different (p<0.05) between the 1st tertile and 3rd tertile
for BMI<24.9.
c The prevalence of metabolic syndrome was significant difference (p<0.05) between the 2 nd and 3rd tertile for
BMI<24.9.
e The prevalence of metabolic syndrome was significantly different (p<0.05) between the 1 st and 2nd tertiles
for BMI:25-29.9.
f The prevalence of metabolic syndrome was significant different (p<0.05) between the 1 st tertile and 3rd tertile
for BMI: 25-29.9.
g The prevalence of metabolic syndrome was significant difference (p<0.05) between the 2 nd and 3rd tertile for
BMI:25-29.9.
h
The prevalence of metabolic syndrome was significantly different (p<0.05) between the 1 st and 2nd tertiles
for BMI≥30.
i The prevalence of metabolic syndrome was significant different (p<0.05) between the 1 st tertile and 3rd tertile
for BMI≥30.
j The prevalence of metabolic syndrome was significant difference (p<0.05) between the 2 nd and 3rd tertile for
BMI≥30.
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Multivariate logistic analyses were performed to evaluate the associations between
the prevalence of metabolic syndrome and the ratio of serum lycopene to serum triglyceride for each BMI status group (Table 7). After adjusting for race, gender, age, alcohol
consumption, smoking and physical activity, there were still significant associations between metabolic syndrome and the ratio of serum lycopene to serum triglyceride for
participants who were normal weight, overweight or obese. In addition, the magnitude of
odds ratio of metabolic syndrome was lower in the 3rd tertile participants who were normal
weight [0.035, 95% CI: 0.016-0.078] than that in participants who were obese [0.131, 95%
CI: 0.104-0.167].
Table 7. Logistic models for the associations between the prevalence of metabolic syndrome and the ratio of serum lycopene to serum triglyceride by BMI status
Ratio of Serum Lycopene to Serum Triglyceride
BMI
1st Tertile
2nd Tertile
3rd Tertile
OR
OR*
95% CI
OR*
95% CI
<24.9
1
0.243
(0.148-0.399)
0.035
(0.016-0.078)
25-29.9
1
0.289
(0.238-0.351)
0.083
(0.062-0.112)
≥30
1
0.359
(0.301-0.428)
0.131
(0.104-0.167)
BMI: body mass index; OR: odds ratio; CI: confidence interval; *: Adjusted for race, gender, age, alcohol
consumption, smoking and physical activity

4.2.4. Stratification by serum levels of lycopene and BMI status
With the ratio of serum concentration of lycopene to serum concentration of triglyceride,
the mean of serum concentration of lycopene was significantly increased from the first
tertile groups to the third tertile groups for all BMI status (Table 8). Very importantly, the
mean of serum concentration of triglyceride was significantly decreased from the first tertile groups to the third tertile groups for all BMI status. Therefore, we can get enough high
relative serum concentration of lycopene for obese participants.
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Table 8. The mean of serum concentration of lycopene and serum concentration of triglyceride stratified by serum levels of lycopene
and BMI status
BMI
Rank
Label
<24.9
25.0-29.9
≥30
N
Mean
95% CI
N
Mean
95% CI
N
Mean
95% CI
lycopene
917
0.23
(0.21-0.24)
1,673
0.30
(0.29-0.31)
1,794
0.30
(0.29-0.32)
(umol/L)
1st
Triglycerides
917
2.19
(1.93-2.45)
1,673
2.89
(2.73-3.04)
1,794
2.92
(2.81-3.03)
(mmol/L)
lycopene
1,283
0.38
(0.37-0.39)
1,580
0.44
(0.43-0.45)
1,522
0.44
(0.43-0.45)
(umol/L)
2nd
Triglycerides
1,283
1.32
(1.29-1.36)
1,580
1.60
(1.55-1.65)
1,522
1.66
(1.61-1.70)
(mmol/L)
lycopene
1,913
0.53
(0.52-0.54)
1,450
0.57
(0.56-0.58)
1,022
0.57
(0.56-0.59)
(umol/L)
3rd
Triglycerides
1,913
0.82
(0.80-0.84)
1,450
0.95
(0.92-0.98)
1,022
1.00
(0.97-1.03)
(mmol/L)
BMI: body mass index; N: number; CI: confidence interval.
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4.3. Increased Levels of Serum Lycopene is Associated with Decreased Mortality
in People with Metabolic Syndrome
4.3.1. Demographic characteristics of participants with metabolic syndrome by lycopene
status
To examine the effect of serum lycopene on survival, three groups of participants with
metabolic syndrome were divided by tertile rank method based on the ratio of serum lycopene to serum triglyceride. The mean ratio of serum concentration of lycopene to serum
concentration of triglyceride was 0.078 (95% CI: 0.076-0.080) in the first tertile group (832
participants), 0.167 (95% CI: 0.165-0.169) in the second tertile group (832 participants)
and 0.365 (95% CI: 0.349-0.381) in the third tertile group (832 participants). The demographic characteristics among the three tertile groups were listed in Table 9.
The distribution of race/ethnicity was significantly different among the three tertile
groups. The percent of African American (21.0%) was higher in the third tertile group than
that (9.3%) in the first tertile group while the percent of Mexican American (17.7%) was
lower in the third tertile group than that (30.9%) in the first tertile group. The percent of
females (52.9%) was higher in the third tertile group than that (48.0%) in the first tertile
group. There was a lower percent of participants aged 60 years and older (30.3%) in the
third tertile group than that (42.4%) in the first tertile group. There were no significant differences among the groups in relation to alcohol consumption. The percent of current
smokers (25.6%) was higher in the first tertile group than that (19.3%) in the third tertile
group. There were a higher percentage of participants with heavy physical activity in the
third tertile group (27.8%) than that (18.8%) in the first tertile group.
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Table 9. Demographic characteristics of participants with metabolic syndrome
levels of lycopene
1st Tertile
2nd Tertile
3rd Tertile
Variable
(N=832)
(N=832)
(N=832)
N
Percent
N
Percent
N
Percent
Race
NH White
433
52.0
497
59.7
464
55.8
NH African Ameri77
9.3
85
10.2
175
21.0
can
Mexican American
257
30.9
193
23.2
147
17.7
Other
65
7.8
57
6.9
46
5.5
Gender
Male
433
52.0
383
46.0
392
47.1
Female
399
48.0
449
54.0
440
52.9
Age (years)
20-39
181
21.8
217
26.1
249
29.9
40-59
298
35.8
309
37.1
331
39.8
≥60
353
42.4
306
36.8
252
30.3
BMI group
Normal weight
64
7.9
38
4.7
49
6.0
Overweight
309
38.1
298
36.5
254
30.8
Obese
439
54.1
481
58.9
521
63.2
Alcohol consumption
No
261
33.0
276
34.9
257
32.7
Moderate
304
38.4
287
36.3
280
35.6
Heavy
226
28.6
228
28.8
250
31.8
Smoking
No
383
46.3
398
48.0
450
54.2
Past
233
28.1
241
29.0
221
26.6
Current
212
25.6
191
23.0
160
19.3
Physical activity
No
416
50.0
370
44.5
317
38.1
259
31.2
267
32.1
284
34.1
Moderate
156
18.8
195
23.4
231
27.8
Heavy

by serum

P-value

<0.0001

0.0328

<0.0001

0.0006

0.5077

0.0067

<0.0001

NH: Non-Hispanic; N: number; BMI: body mass index.

4.3.2. Mortality by lycopene status in adults with metabolic syndrome
The NHANES 2001-2006 Linked Mortality File provided mortality information for participants involved in NHANES interview (2001-2006) through December 31, 2011. Of the
832 participants with metabolic syndrome in the first tertile group, 83 participants had died.
Of the 832 participants with metabolic syndrome in the second tertile group, 50 participants had died. Of the 832 participants with metabolic syndrome in the third tertile group,
43 participants died. The proportion of individuals died was significantly lower in the third
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tertile group (5.2%, 95% CI: 3.7-6.7) or in the second tertile group (6.0%, 95% CI: 4.4-7.6)
compared to the first tertile group (10.0%, 95% CI: 7.9-12.0) among participants with metabolic syndrome.
4.3.3. An association between the serum lycopene and mortality in adults with metabolic
syndrome
We conducted a Cox model to estimate the hazard ratios (HR) and 95% CI of mortality
adjusting for race, gender, age groups, BMI status, smoking status, alcohol consumption,
physical activity and cancers. The final model included race, age group, BMI status, smoking status, physical activity and serum levels of lycopene. Compared with the first tertile
group (HR=1.0), both the third tertile (HR=0.63, 95% CI: 0.43-0.91) and the second tertile
groups (HR=0.63, 95% CI: 0.43-0.94) had a significantly lower hazard ratios of mortality
for participants with metabolic syndrome after adjusting for these variables (Table 10).
Table 10. Cox models for the associations between mortality and serum levels of lycopene
for participants with metabolic syndrome
Serum Lycopene
Hazard Ratio*
95% CI
st
1 tertile
1.0
N/A
nd
2 tertile
0.63
(0.43-0.94)
3rd tertile

0.63

(0.43-0.91)

CI: confidence interval; N/A: not applicable; *Adjusted for race, gender, age groups, BMI status, smoking
status, alcohol consumption, physical activity and cancers.

4.4. An Additive Effect of Physical Activity and Serum Lycopene on the Prevalence
of Metabolic Syndrome among Overweight and Obese Adults
4.4.1. Independent effect of physical activity
Of the 9,038 participants who were overweight or obese, there were 3,319 (36.7%)
participants with metabolic syndrome. The prevalence of metabolic syndrome varied according to the levels of physical activity (Figure 9). The prevalence of metabolic syndrome
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in participants with heavy physical activity (26.8%, 95% CI 24.9-28.7) was significantly
lower compared to participants with no physical activity (43.3%, 95% CI 41.4-45.2).
4.4.2. Independent effect of serum lycopene
To estimate the association between the prevalence of metabolic syndrome and the
ratio of serum lycopene to serum triglyceride, participants were divided by tertile rank
method according to the ratio of serum lycopene to serum triglyceride. The mean ratio of
serum lycopene to serum triglyceride was 0.107 (95% CI: 0.105-0.109) for the first tertile
group, 0.249 (95% CI: 0.246-0.252) for the second tertile group and 0.592 (95% CI: 0.5800.605) for the third tertile group. There was a significantly dose-dependent decrease the
percent of metabolic syndrome from the first tertile group (63.2%, 95% CI: 61.2-65.2), the
second tertile group (38.6%, 95% CI: 36.6-40.5) to the third tertile group (13.8%, 95% CI:
12.3-15.3) (Figure 9).
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Figure 9. The association between metabolic syndrome and physical activity or the ratio
of serum lycopene to serum triglyceride

#

The prevalence of metabolic syndrome was significantly different (p<0.05) between the no physical activity
and heavy physical activity.
a The prevalence of metabolic syndrome was significantly different (p<0.05) between the 1 st and 2nd tertiles.
b The prevalence of metabolic syndrome was significant different (p<0.05) between the 1 st tertile and 3rd tertile.
c The prevalence of metabolic syndrome was significant difference (p<0.05) between the 2 nd and 3rd tertile.

4.4.3. An additive effect of physical activity and serum lycopene
To estimate the additive effect of physical activity and serum lycopene on the prevalence of metabolic syndrome, we combined all the levels of physical activity and the levels
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of serum lycopene. There was a significant interaction effect between the combined physical activity and serum lycopene and BMI status on the prevalence of metabolic syndrome.
BMI is an effect modifier of the association between the combined physical activity and
serum lycopene and metabolic syndrome. Therefore, we showed the additive effects of
physical activity and serum lycopene stratified by BMI status, overweight and obesity (Table 11).
For overweight participants, the prevalence of metabolic syndrome was significantly
reduced with increased levels of serum lycopene for all physical activity levels. For example, the prevalence of metabolic syndrome reduced from 54.3% in the first tertile to 11.6%
in the third tertile for participants without physical activity. The prevalence of metabolic
syndrome reduced from 53.5% in the first tertile to 8.6% in the third tertile for participants
with moderate physical activity. The prevalence of metabolic syndrome reduced from 39.0%
in the first tertile to 2.6% in the third tertile for participants with heavy physical activity.
The prevalence of metabolic syndrome was significantly reduced in participants with
heavy physical activity compared to participants without physical activity for all levels of
serum lycopene. For example, in the first tertile, the prevalence of metabolic syndrome
reduced from 54.3% among participants without physical activity to 39.0% among participants with heavy physical activity. In the second tertile, the prevalence of metabolic
syndrome reduced from 23.9% among participants without physical activity to 15.1%
among participants with heavy physical activity. In the third tertile, the prevalence of metabolic syndrome reduced from 11.6% among participants without physical activity to 2.6%
among participants with heavy physical activity. Therefore, there was an additive effect of
physical activity and serum lycopene on metabolic syndrome.
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For obese participants, the prevalence of metabolic syndrome was still significantly
reduced with increased levels of serum lycopene for all physical activity status. For example, the prevalence of metabolic syndrome reduced from 69.6% in the first tertile to 19.8%
in the third tertile for participants without physical activity. The prevalence of metabolic
syndrome reduced from 73.8% in the first tertile to 24.0% in the third tertile for participants
with moderate physical activity. The prevalence of metabolic syndrome reduced from 68.3%
in the first tertile to 21.5% in the third tertile for participants with heavy physical activity.
However, the prevalence of metabolic syndrome was not significantly different between participants with heavy physical activity and participants without physical activity for
all levels of serum lycopene. For example, in the first tertile, the prevalence of metabolic
syndrome was not different between participants without physical activity (69.6%) and
participants with heavy physical activity (68.3%). In the second tertile, the prevalence of
metabolic syndrome was not different between participants without physical activity
(46.2%) and participants with heavy physical activity (42.2%). In the third tertile, the prevalence of metabolic syndrome was not different between participants without physical
activity (19.8%) and participants with heavy physical activity (21.5%).Therefore, there was
no an additive effect of physical activity and serum lycopene on metabolic syndrome.
Table 11. The prevalence of metabolic syndrome by the combination of the levels of physical activity and the levels of serum lycopene stratified by BMI status
Serum Lycopene
st
BMI
Physical
1 Tertile
2nd Tertile
3rd Tertile
Status
Activity
%
95% CI
%
95% CI
%
95% CI
Overweight

Obesity

None
Moderate
Heavy
None
Moderate
Heavy

54.3
53.5
39.0
69.6
73.8
68.3

(49.0-59.7)
(48.1-59.0)
(33.1-45.0)
(65.9-73.2)
(69.5-78.1)
(62.9-73.6)

BMI: body mass index; CI: confidence interval.

23.9
27.9
15.1
46.2
45.2
42.2

(19.7-28.2)
(23.8-32.1)
(10.8-19.4)
(41.6-50.9)
(39.5-51.0)
(36.2-48.3)

11.6 (7.5-15.7)
8.6
(5.1-12.1)
2.6
(1.3-3.9)
19.8 (13.7-25.9)
24.0 (18.6-29.5)
21.5 (15.1-27.9)
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4.4.4. Logistic regression results
Logistic regression analyses were performed to evaluate the association between the
prevalence of metabolic syndrome and the combination of the levels of physical activity
and the levels of serum lycopene, and to calculate the ORs and 95% CI. Table 12 show
the ORs and 95%CI after adjusting for race, gender, age group, alcohol consumption and
smoking status in the risk of metabolic syndrome (Table 12).
For overweight participants, after adjusting for race, gender, age group, alcohol consumption and smoking status, the magnitude of OR was significantly reduced with
increased levels of serum lycopene for all physical activity levels. For example, the magnitude of OR reduced from 1 in the first tertile to 0.12 (95% CI: 0.07-0.19) in the third tertile
for participants without physical activity. The magnitude of OR reduced from 0.94 (95% CI:
0.67-1.32) in the first tertile to 0.08 (95% CI: 0.05-0.13) in the third tertile for participants
with moderate physical activity. The magnitude of OR reduced from 0.65 (95% CI: 0.470.90) in the first tertile to 0.03 (95% CI: 0.02-0.06) in the third tertile for participants with
heavy physical activity. The magnitude of OR was also significantly reduced with increased level of physical activity for serum lycopene levels. For example, in the first tertile,
the magnitude of OR reduced from 1 among participants without physical activity to 0.65
(95% CI: 0.47-0.90) among participants with heavy physical activity. In the third tertile, the
magnitude of OR reduced from 0.12 (95% CI: 0.07-0.19) among participants without physical activity to 0.03 (95% CI: 0.02-0.06) among participants with heavy physical activity.
Therefore, therefore, there was an additive effect of physical activity and serum lycopene
on metabolic syndrome.
For obese participants, after adjusting for race, gender, age group, alcohol consumption and smoking status, the magnitude of OR was significantly reduced with increased
levels of serum lycopene for all physical activity levels. For example, the magnitude of OR
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reduced from 1 in the first tertile to 0.12 (95% CI: 0.08-0.17) in the third tertile for participants without physical activity. The magnitude of OR reduced from 1.16 (95% CI: 0.871.56) in the first tertile to 0.15 (95% CI: 0.11-0.22) in the third tertile for participants with
moderate physical activity. The magnitude of OR reduced from 0.92 (95% CI: 0.67-1.27)
in the first tertile to 0.14 (95% CI: 0.09-0.20) in the third tertile for participants with heavy
physical activity. However, the magnitude of OR was not significantly different between
participants with heavy physical activity and participants without physical activity for all
levels of serum lycopene. For example, in the first tertile, the magnitude of OR was not
different between participants without physical activity (1) and participants with heavy
physical activity (0.92, 95% CI: 0.67-1.27). In the second tertile, the magnitude of OR was
not different between participants without physical activity (0.37, 95% CI: 0.28-0.50) and
participants with heavy physical activity (0.35, 95% CI: 0.26-0.47). In the third tertile, the
magnitude of OR was not different between participants without physical activity (0.12, 95%
CI: 0.08-0.17) and participants with heavy physical activity (0.14, 95% CI: 0.09-0.20).
Therefore, there was no an additive effect of physical activity and serum lycopene on metabolic syndrome.
Table 12. Multivariate logistic models for the associations between the prevalence of metabolic syndrome by the combination of the levels of physical activity and the levels of
serum lycopene stratified by BMI status
Serum Lycopene
Physical
st
1 Tertile
2nd Tertile
3rd Tertile
BMI Status
Activity
OR*
95% CI
OR*
95% CI
OR*
95% CI
None
1
N/A
0.28 (0.19-0.39) 0.12 (0.07-0.19)
Overweight Moderate 0.94 (0.67-1.32) 0.29 (0.21-0.42) 0.08 (0.05-0.13)
Heavy
0.65 (0.47-0.90) 0.18 (0.12-0.26) 0.03 (0.02-0.06)
None
1
N/A
0.37 (0.28-0.50) 0.12 (0.08-0.17)
Obesity
Moderate 1.16 (0.87-1.54) 0.38 (0.29-0.51) 0.15 (0.11-0.22)
Heavy
0.92 (0.67-1.27) 0.35 (0.26-0.47) 0.14 (0.09-0.20)
BMI: body mass index; OR: odds ratio; CI: confidence interval; N/A: not applicable; * Adjusted for race, gender,
age group, alcohol consumption and smoking status in the risk of metabolic syndrome.
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4.4.5. The mean ratio of serum lycopene to serum triglyceride by physical activity
The mean ratio of serum lycopene to serum triglyceride was significantly higher in
participants with heavy physical activity than participants without physical activity for all
BMI status (Table 13). For example, among overweight participants, the ratio increased
from 0.31 (95% CI: 0.30-0.33) in participants with no physical activity to 0.42 (95% CI:
0.40-0.44) in participants with heavy physical activity. For example, among obese participants, the ratio increased from 0.27 (95% CI: 0.25-0.28) in participants with no physical
activity to 0.34 (95% CI: 0.33-0.36) in participants with heavy physical activity. The mean
ratio of serum lycopene to serum triglyceride was significantly higher with increased levels
of physical activity.
Table 13. The mean ratio of serum lycopene to serum triglyceride by physical activity
Mean Ratio of Serum
BMI Status Physical Activity
N
Lycopene to Serum
95% CI
Triglyceride
None
1,883
0.31
(0.30-0.33)
Overweight Moderate
1,414
0.35
(0.33-0.37)
Heavy
1,403
0.42
(0.40-0.44)
None
1,936
0.27
(0.25-0.28)
Obesity
Moderate
1,366
0.29
(0.28-0.31)
Heavy
1,036
0.34
(0.33-0.36)
BMI: body mass index; N: number; CI: confidence interval.

4.5. An Additive effect of Physical Activity and Serum Lycopene on Mortality in
Adults with Metabolic Syndrome
4.5.1. The mortality among adults with metabolic syndrome by physical activity
The combination of NHANES 2001–2006 included 3,868 participants who were at
least 20 years of age with metabolic syndrome. Participants who had missing information
on serum lycopene and serum triglyceride and physical activity (n=176) were excluded. In
addition, individuals who had diabetes or heart disease or stroke (n=1,130) and/or who

66
died from diabetes or heart disease or stroke (n=67) were excluded. As a result, the final
sample included 2,495 individuals.
The percent of individuals who had died was significantly reduced in participants with
heavy physical activity (3.1%) compared to the participants with no physical activity (9.3%)
(Table 14).
Table 14. The percentage of individuals with metabolic syndrome who had died: Stratification by physical activity level
Physical Activity
N
% of Individuals Died
95% CI
None

1,103

9.3

(7.6-11.1)

Moderate

810

6.7

(4.9-8.3)

Heavy

582

3.1

(1.7-4.5)

N: number; CI: confidence interval.

4.5.2. Mortality by the levels of serum lycopene among adults with metabolic syndrome
To examine the effect of serum lycopene on death, participants with metabolic syndrome were divided by tertile rank method based on the ratio of serum lycopene to serum
triglyceride. The mean ratio of serum lycopene to serum triglyceride was 0.078 (95% CI:
0.076-0.080) in the first tertile group, 0.167 (95% CI: 0.165-0.169) in the second tertile
group and 0.365 (95% CI: 0.349-0.381) in the third tertile group. The proportion of individuals who had died was significantly reduced in the third tertile group (5.2%) compared to
the first tertile group (9.9%) among participants with metabolic syndrome (Table 15).
Table 15. The percentage of individuals with metabolic syndrome who had died: Stratified
by serum lycopene levels
Serum Lycopene
N
% of Individuals Died
95% CI
1st tertile
2nd tertile
3rd tertile
N: number; CI: confidence interval.

831
832
832

9.9
6.0
5.2

(7.8-11.9)
(4.4-7.6)
(3.7-6.7)
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4.5.3. Mortality by physical activity and serum lycopene among adults with metabolic
syndrome
Due to the second tertile group and the third tertile group having similar mortality rate,
we combined these two groups. The proportion of individuals who died was significantly
reduced in participants with higher levels of serum lycopene and heavy physical activity
(2.8%, 95% CI: 1.2-4.4) compared to participants with higher levels of serum lycopene
and no physical activity (7.7%, 95% CI: 5.7-9.7) (Table 16). The proportion of individuals
who had died was similar between participants with higher levels of serum lycopene and
heavy physical activity (2.8%, 95% CI: 1.2-4.4) and participants with lower levels of serum
lycopene and heavy physical activity (3.8%, 95% CI: 0.8-6.8).
Table 16. The proportion of individuals who had died in metabolic syndrome by physical
activity and serum lycopene levels
Serum Lycopene
1st Tertile

Physical Activity

None
Moderate
Heavy

2nd and 3rd Tertile

N

% Died

95% CI

N

% Died

95% CI

416
259
156

12.0
10.0
3.8

(8.9-15.1)
(6.4-13.7)
(0.8-6.8)

687
551
426

7.7
5.1
2.8

(5.7-9.7)
(3.2-6.9)
(1.2-4.4)

N: number; CI: confidence interval.

4.5.4. Additive effects of physical activity and serum lycopene on mortality among adults
with metabolic syndrome
We conducted Cox analyses to estimate hazard ratios and 95% CIs of mortality after
adjusting for race, gender, age, smoking status, alcohol consumption (Table 17). There
was a significant effect of serum lycopene on mortality for participants with metabolic syndrome. However, there was no a significant additive effect of physical activity and serum
lycopene on mortality.
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Table 17. Hazard ratios (HRs) and 95% CI of mortality in metabolic syndrome by combing
of physical activity and lycopene levels in the multivariate logistic regression models
Serum Lycopene Level
1st Tertile

Physical Activity

2nd & 3rd Tertiles

HR*

95% CI

HR*

95% CI

1

N/A

0.651

(0.430-0.985)

Moderate

0.663

(0.398-1.106)

0.395

(0.241-0.650)

Heavy

0.506

(0.215-1.194)

0.317

(0.162-0.621)

None

CI: confidence interval.

4.5.5. The mean ratio of serum lycopene to serum triglyceride by physical activity among
adults with metabolic syndrome
The mean ratio of serum lycopene to serum triglyceride was significantly higher in
participants with heavy physical activity than participants without physical activity (Table
18). For example, the ratio increased from 0.19 (95% CI: 0.18-0.20) in participants without
physical activity to 0.23 (95% CI: 0.22-0.24) in participants with heavy physical activity.
Table 18. The mean ratio of serum lycopene to serum triglyceride by physical activity
Mean of Ratio of Serum
Physical Activity
N
Lycopene to Serum Tri95% CI
glyceride
None
1,103
0.19
(0.18-0.20)
Moderate
810
0.22
(0.20-0.23)
Heavy
582
0.23
(0.22-0.24)
N: number; CI: confidence interval.

4.6. Summary of Findings
In this chapter, we presented the main findings from the analyses of NHANES data.
First, we found that BMI had an important influence on the association between serum
lycopene and metabolic syndrome. A higher serum concentration of lycopene was significantly associated with a lower prevalence of metabolic syndrome. However, these
associations were only significant for normal weight and overweight participants, but not
for obese participants. Secondly, the association between the ratio of serum lycopene to
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serum triglyceride and the prevalence of metabolic syndrome was significant not only for
normal weight and overweight participants, but also for obese participants.
Thirdly, a high level of serum lycopene was significantly associated with a decreased
mortality among participants with metabolic syndrome. Metabolic syndrome participants
with a higher level of serum lycopene (the mean ratio of serum lycopene to serum triglyceride=0.364) had a significantly smaller proportion of death (p<0.0001) than those with a
lower level of serum lycopene (the mean ratio=0.077). Even after adjusting for race, age,
BMI status, smoking and physical activity, metabolic syndrome participants with a higher
level of serum lycopene still had a significantly reduced hazard ratio of mortality than those
with a lower level of serum lycopene (p<0.05). Fourthly, physical activity and serum lycopene had an additive effect on the prevalence of metabolic syndrome for overweight
individuals but not for obese individuals. Fifthly, there was not an additive effect of physical
activity and serum lycopene on mortality.
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CHAPTER 5 DISCUSSION
5.1. Discussion
5.1.1. Health effects of lycopene on obese individuals
Metabolic syndrome is an important public health issue. About one in three United
States adult aged 20 years and older has metabolic syndrome [2]. Metabolic syndrome is
a direct risk factor for chronic diseases, such as cardiovascular diseases, diabetes mellitus, stroke and cancers [1, 3-5 and 160]. The growing prevalence of metabolic syndrome
is strongly related to the increasing prevalence of overweight and obesity [2, 12]. Therefore, preventing overweight and obesity is an important strategy to reduce the prevalence
of metabolic syndrome. However, interventions related to overweight and obesity have not
achieved expected results; more than one-third of adults and 17% of youth in the United
States are obese [75]. Therefore, reducing the development of metabolic syndrome in
individuals who are overweight and obese may be an innovative approach to reduce the
total burden of chronic diseases in the general population.
As a natural nutrient, the higher level of lycopene is significantly associated with the
lower prevalence of metabolic syndrome in the general population [23-25]. The biological
mechanisms by which lycopene reduces the risk of metabolic syndrome include alleviating
oxidative stress and decreasing inflammation [18-22, 126]. Studies show that the increased risk of metabolic syndrome in individuals who are overweight and obese
contributes to increased inflammation and oxidative stress production [11, 13 and 161].
Therefore, increasing serum concentration of lycopene is a potential strategy to decrease
the risk of developing metabolic syndrome in individuals who are overweight and obese.
However, despite the cumulating evidence to support the health effects of lycopene, it is
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not clear whether lycopene has similar effects among individuals who are overweight or
obese.
For this reason, recently, more studies about the health effects of lycopene began to
focus on individuals who were overweight and obese [32-37]. However, the findings from
these studies have been inconclusive. There are two potential reasons for conflicting results among the studies: one potential reason is that the participants had different BMI
levels [34, 35], and the other reason is that the participants had different serum concentrations of lycopene [33, 37].
The same “high” serum concentrations of lycopene for individuals with a lower BMI
level may not produce the same health effects in individuals with a higher BMI level because there is more inflammation and oxidative stress production in individuals who are
obese or overweight [34, 35]. Our results strongly supported the idea that with the same
serum concentration of lycopene, lycopene is significantly associated with the prevalence
of metabolic syndrome only for normal weight and overweight individuals, but not for
obese individuals. The biological mechanisms by which lycopene reduces the risk of metabolic syndrome mainly depend on alleviating oxidative stress and decreasing
inflammation [18-22, 126]. Therefore, the effects of lycopene on alleviating oxidative stress
and decreasing inflammation may predict the effects of lycopene on metabolic syndrome.
With the same level of serum concentrations of lycopene, the effects of serum lycopene
on the prevalence of metabolic syndrome are only significant for normal weight or overweight individuals, not for obese individuals.
However, accumulating evidence also supports that lycopene inhibited inflammation
and oxidative stress in a dose-dependent manner [38, 39]. Therefore, we hypothesized
that highly efficient serum concentration of lycopene may be needed to produce significant
effects on participants who are obese. Unfortunately, due to the observational nature of
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the study, the serum concentration of lycopene was relatively low among obese participants (0.642 umol/L in the third tertile group) which was also the same as the serum
concentration of lycopene among normal weight participants (0.642 umol/L in the third
tertile group). In a future observational study, a new analysis method for serum lycopene
(for example, relative serum lycopene to the amount of inflammation and oxidative stress
in the body) may be used to confirm the hypothesis.
5.1.2. The ratio of serum lycopene to serum triglyceride can predict the health effect of
lycopene on metabolic syndrome
Health effects of serum lycopene depend not only on the serum concentration of lycopene, but also on the amount of inflammation and/or oxidative stress in the body;
therefore, we hypothesized that the ratio of serum concentration of lycopene to the amount
of inflammation and/or oxidative stress could better predict the association between serum
lycopene and the health effects. There is no method to directly measure the amount of
inflammation and/or oxidative stress in the body. Given the strong associations between
oxidative stress [41] and inflammation [42], this study used serum triglyceride to represent
the amount of inflammation and/or oxidative stress.
To verify our hypothesis, we examined the association between the ratio of serum
concentration of lycopene to serum concentration of triglyceride and the prevalence of
metabolic syndrome. As expected, our study showed that higher ratios of serum concentration of lycopene to serum concentration of triglyceride were significantly associated with
the reduced prevalence of metabolic syndrome. This result is consistent with findings of
previous studies with serum concentration of lycopene as exposure [23-25]. Furthermore,
the association between the ratio of serum lycopene to serum triglyceride and the prevalence of metabolic syndrome is significant not only for normal weight and overweight
participants, but also for obese participants.
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5.1.3. Comparison of two methods for the association between serum lycopene and metabolic syndrome
We compared the associations between metabolic syndrome and lycopene with different measures of serum lycopene: serum concentration of lycopene and the ratio of
serum concentration of lycopene to serum concentration of triglyceride. With the serum
concentration of lycopene, the association between metabolic syndrome and lycopene
was significant only for normal weight and overweight participants, not for obese participants. With the ratio, the association between metabolic syndrome and lycopene was
significant not only for normal weight and overweight participants, but also for obese participants. What caused the different results? We hypothesized that the different results
may be related to the difference in levels of inflammation and oxidative stress between
normal weight/overweight participants and obese participants. Therefore, we compared
the mean serum concentrations of lycopene and serum concentrations of triglyceride
among all combination of serum levels of lycopene and BMI.
With serum concentration of lycopene (Table 4), the mean serum concentration of
lycopene was significantly increased from the first tertile group to the third tertile group for
all BMI levels while the mean serum concentration of triglyceride was different among the
three BMI levels. The mean serum concentrations of triglyceride was not significantly different between the third tertile group and the first tertile group for normal weight and
overweight participants while the mean serum concentration of triglyceride was significantly different between the third tertile group and the first tertile group for obese
participants. Therefore, the serum concentrations of lycopene considered to be “high” for
individuals with a lower BMI does not produce the same health effects in individuals with
a higher BMI because there is more inflammation and oxidative stress production in people with a higher BMI [34, 35].
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With the ratio of serum concentration of lycopene to serum concentration of triglyceride
(Table 8), the situation is different. The mean serum concentration of lycopene was significantly increased from the first tertile group to the third tertile group for all BMI levels.
Also, the mean serum concentration of triglyceride was significantly decreased from the
first tertile group to the third tertile group for all BMI levels. Therefore, the ratio method can
provide the same conditions (with similar serum concentration of lycopene and serum
concentration of triglyceride) for all BMI levels. This may mean that health effects of lycopene are significant not only for normal weight and overweight participants, but also for
obese individuals.
In addition, with the serum concentration of lycopene (Table 4), the health effects of
lycopene were not different between the second tertile group and third tertile group for
normal weight and overweight participants. However, the plateau effect of lycopene may
be an alternative explanation—it is possible that the serum lycopene was not high enough
in the third tertile group when compared to the second tertile group. With the ratio of serum
lycopene to serum triglyceride (Table 8), the health effects of lycopene were significantly
different between the second tertile group and third tertile group for all BMI levels because
there was a relatively higher concentration of serum lycopene in the third tertile group than
in the second tertile group. Therefore, consistent with findings of previous studies [38, 39],
this study showed that there is a biologically gradient relationship between the ratio of
serum lycopene to serum triglyceride and metabolic syndrome.
The findings of this study indicate that if the relative level of serum lycopene, according
to the amount of inflammation and/or oxidative stress, is higher, then serum lycopene may
produce significant health effects no matter what the actual serum concentration of lycopene is. This means that a high level of serum lycopene could have significant health
effects among adults regardless of their BMI levels.
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5.1.4. The health effect of lycopene on mortality among individuals with metabolic syndrome
Serum lycopene can reduce the prevalence of metabolic syndrome among adults.
However, whether serum lycopene still has positive health effects among individuals who
have developed a health condition with metabolic syndrome is not clear. We hypothesized
that serum lycopene can reduce the mortality in individuals with metabolic syndrome.
To test our hypothesis, we examined the health effect of serum lycopene on mortality
among NHANES participants with metabolic syndrome. As expected, our study clearly
showed that the higher level of serum lycopene was significantly associated with the lower
mortality among participants with metabolic syndrome. Therefore, even if individuals who
have been classified as having metabolic syndrome, serum lycopene can still help reduce
the risk of mortality for them.
5.1.5. The additive health effects of physical activity and lycopene on morbidity of metabolic syndrome
In addition to lycopene, physical activity can reduce the risk of metabolic syndrome
[43-45]. However, the effects of physical activity or lycopene alone are insufficient to substantially reduce the risk of metabolic syndrome for overweight and obese individuals [44].
Therefore, exploring the additive effects between physical activity and serum lycopene is
important for further reducing the risk of metabolic syndrome among individuals who are
overweight and obese.
Our results showed that the additive effects of physical activity and serum lycopene
differs by the BMI level. The additive effect was only found among overweight individuals
but not for obese individuals. There are two potential explanations for the different effects
of physical activity and serum lycopene on the prevalence of metabolic syndrome between
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overweight individuals and obese individuals. One explanation is that physical activity reduces the prevalence of metabolic syndrome among obese individuals mainly through
other means, such as weight control and an increased level of serum lycopene. Research
has shown that physical activity has complex mechanisms on the prevalence of metabolic
syndrome, such as controlling weight [162], reducing serum concentration of triglyceride,
increasing high-density lipoprotein, improving insulin sensitivity, reducing blood pressure
and decreasing inflammation reactions and inducting an anti-inflammatory environment
[46-48]. Our results indicated that the increasing the level of serum lycopene may be one
of the mechanisms by which physical activity reduces the risk of metabolic syndrome.
Consistent with this hypothesis, Cheriyath et al. found that body weight is a more important
determinant than physical activity in the development of metabolic syndrome [44]. Therefore, the additive effect of physical activity and serum lycopene among obese individuals
may need to be analyzed using more complex conceptual and analytical models that include weight control and serum lycopene change.
Another explanation is that self-reported physical activity is less accurate among
obese individuals than normal weight and overweight individuals. Serum lycopene is an
objective variable, while physical activity is a subjective variable in this study. Inaccurate
self-reported physical activity will lead to misclassifications. Accumulating evidence supports that obese participants overestimate their vigorous physical activity levels and
misclassify the intensity of physical activity than normal weight and overweight participants
[163-165]. This means that the misclassification of physical activity is unrelated to classification of metabolic syndrome. As a result, the misclassification of physical activity is a
non-differential misclassification, which may have led to results toward the null for obese
participants.
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5.1.6. The additive health effects of physical activity and lycopene on mortality of metabolic syndrome
For mortality, consistent with the previous findings, physical activity is significantly associated with reduced mortality in patients with metabolic syndrome [69]. Our results also
showed that higher serum lycopene levels are significantly associated with reduced mortality in participants with metabolic syndrome. We did not find a significant additive effect
of physical activity and serum lycopene on mortality for participants with metabolic syndrome. However, increasing serum levels of lycopene may be one of the mechanisms by
which physical activity reduces the risk of mortality among individuals with metabolic syndrome.
In summary, our findings support our conceptual model (Figure 10). Serum lycopene
and physical activity can decrease the risk of metabolic syndrome among adults. Serum
lycopene and physical activity have an additive effect on metabolic syndrome for overweight individuals, not for obese individuals. Serum lycopene and physical activity can
significantly decrease the risk of mortality among individuals with metabolic syndrome.
Serum lycopene and physical activity do not have an additive effect on reducing mortality
among individuals with metabolic syndrome. However, increased serum lycopene may be
one of the mechanisms by which physical activity reduces the risk of morbidity and mortality of metabolic syndrome.
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Figure 10. A conceptual model linking lycopene, physical activity, overweight/obesity, metabolic syndrome and mortality

5.2. Strengths and Limitations of the Study
Strengths of this study include a large and representative sample and well-characterized data with many potential risk factors. First, we found that there was a significant
interaction effect between serum lycopene and BMI status on metabolic syndrome. Therefore, BMI was an effect modifier of the association between serum lycopene and metabolic
syndrome. With effect modification, stratified analysis is an appropriate method to examine the association between exposure and outcome. Therefore, the association between
serum lycopene and metabolic syndrome was analyzed separately for normal weight,
overweight and obese participants in this study. Secondly, the health effect of serum lycopene on the prevalence of metabolic syndrome may depend not only on serum
concentration of lycopene, but also on the amount of inflammation and/or oxidative stress;
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therefore, we use the ratio of serum concentration of lycopene to the amount of inflammation and/or oxidative stress as a new measure of lycopene in this study. Our result also
supports the idea that the ratio of the serum concentration of lycopene to the amount of
inflammation and/or oxidative stress can better predict the association between lycopene
and positive health effects than only with serum concentration of lycopene.
Limitations of the study should be also noted. First, as stated previously, a self-report
may have produced non-differential and differential misclassification of physical activity
levels and other variables. Secondly, although there were strong and dose-response associations between lycopene and the morbidity and mortality of metabolic syndrome, it is
not possible to show a causal inference between serum lycopene and metabolic syndrome
due to the cross-sectional nature of the study. Thirdly, the effect of serum lycopene may
be underestimated in the present study because serum lycopene may be higher in clinical
trials when subjects take more fruits and vegetables rich in lycopene or more lycopene
supplement than in the current study. Lastly, the effect of changes of serum lycopene on
the risk of mortality over time could not be analyzed because of the cross-sectional design
of NHANES.
5.3. Conclusion
From a nationally representative sample of the United States adults, our study adds
new evidence that the ratio of serum lycopene to serum triglyceride has significant associations with morbidity and mortality of metabolic syndrome. However, due to some
limitations of the study, the findings from the study cannot directly provide clinical recommendations, but can provide a new analysis method for future studies between lycopene
and health effects.
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5.4. Suggestions for the Future Research
Due to being a part of a cross-sectional study, the current study is difficult to build a
causal inference between serum lycopene and metabolic syndrome. Further prospective
studies with the incidence of metabolic syndrome are needed to confirm these primary
results. For example, a cohort of participants may be randomly selected from a community. Then, these participants may be randomly assigned into three groups, a control
group, a low-tomato diet and a high-tomato diet. These participants could be followed-up
for around 10 years and periodically tested for serum concentration of lycopene and serum
concentration of triglyceride and estimated metabolic syndrome condition. Then, we could
estimate the causal effect of serum lycopene on the incidence of metabolic syndrome.
According to our findings, even among obese individuals, if the relative level of serum
lycopene according to the amount of inflammation and/or oxidative stress is higher, serum
lycopene may produce significant health effects no matter what actual serum concentration of lycopene is. Therefore, highly efficient serum concentration of lycopene can
produce significant effects on participants who are obese. Thus, future research should
test if serum lycopene has a dose-dependent manner on the incidence of metabolic syndrome among obese individuals.
In addition, future research should also determine what the cut-off value of the ratio of
serum concentration of lycopene to the amount of inflammation and/or oxidative stress in
the body is for substantially reducing the prevalence of metabolic syndrome, separately
for normal weight, overweight and obese individuals. This information on the effects of
lycopene for individuals with different BMI statuses is expected to be very important for
future dosage recommendations.
Although serum triglyceride is strongly associated with inflammation and oxidative
stress in the body, serum triglyceride is not a direct measure of inflammation or oxidative
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stress. Therefore, more direct measures of inflammation and/or oxidative stress, such as
Interleukin (TNF-α, IL-8) and reactive oxygen species (ROS), are needed to estimate the
health effects of lycopene based on the ratio of serum concentration of lycopene to the
amount of inflammation and oxidative stress.
For the health effect of serum lycopene on mortality among participants with metabolic
syndrome, although our findings support the positive health effect of lycopene on mortality
for individuals with metabolic syndrome, there are two issues that need to be solved in
future research. One issue is the change of serum lycopene during the whole followingup time. Due to the cross-sectional design of NHANES, we do not know if these participants have changed their serum concentration of lycopene during the following-up time.
Therefore, a new prospective study for the health effect of lycopene on mortality should
have periodic tests of serum concentration of lycopene. Another issue is what causes the
reduced mortality among these individuals with a higher level of serum lycopene. In this
study, we only know higher serum lycopene has an association with a lower mortality
among individuals with metabolic syndrome. Future research can help us to understand
what specific disease-related mortality could be reduced in individuals with a higher level
of serum lycopene.
For the additive health effect of physical activity and lycopene, serum lycopene is an
objective variable; however, physical activity is a self-reported variable which is less accurate among obese individuals than individuals who are normal weight and overweight.
Therefore, inaccurate self-reported physical activity will lead to a misclassification error in
current study. Therefore, in future research, more objective measurements of physical
activity, such as an accelerometer measurement, should verify the additive effect of physical activity and serum lycopene.
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In addition, physical activity has complex mechanisms on the morbidity and mortality
of metabolic syndrome, such as controlling weight, reducing serum concentration of triglyceride, increasing high-density lipoprotein, improving insulin sensitivity, reducing blood
pressure and decreasing inflammation reactions and inducting an anti-inflammatory environment. Therefore, future research should estimate the possible additive effect of
physical activity and lycopene on metabolic syndrome and mortality when all these variables are taken into account of in the study.
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